Otsuka Pharmaceutical Development & Commercialization, Inc.
Digital Therapeutic
CT-152
REVISED CLINICAL PROTOCOL
A Multi-center, Randomized, Controlled Trial to Evaluate the Effectiveness of a Digital 
Therapeutic (CT-152) as Adjunctive Therapy in Adult Subjects Diagnosed with Major 
Depressive Disorder
Lay Person Short Title: Trial to Evaluate the Effectiveness of a Digital Therapeutic 
(CT-152) as Adjunctive Therapy in Adult Subjects Diagnosed with Major Depressive 
Disorder
Protocol No. 345-201-[ZIP_CODE]
CONFIDENTIAL âŽ¯ PROPRIETARY INFORMATION
Clinical Development Phase: Pi[INVESTIGATOR_851911]: Otsuka Pharmaceutical Development & 
Commercialization, Inc.
Immediately Reportable Event 
Amendment 2 Approval: 03 Nov 2021&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
Protocol No. 345-201-[ZIP_CODE]
2
Confidential - Proprietary Information Approval: [ADDRESS_1184494] of In-text Figures ...................................................................................8
1 Protocol Summary................................................................................9
1.1 Synopsis ..............................................................................................................9
1.2 Schema ..............................................................................................................21
1.3 Schedule of Assessments ..................................................................................23
2 Introduction ........................................................................................27
2.1 Trial Rationale...................................................................................................27
2.2 Background .......................................................................................................27
2.3 Known and Potential Risks and Benefits ..........................................................30
3 Objectives and Endpoints..................................................................31
4 Trial Design.........................................................................................32
4.1 Type/Design of Trial .........................................................................................[ADDRESS_1184495] Selection and Numbering .....................................................................36
5.2 Eligibility Criteria .............................................................................................36
5.2.1 Inclusion Criteria ............................................................................................37
5.2.2 Exclusion Criteria ...........................................................................................38
5.3 Lifestyle Considerations....................................................................................40
5.4 Screen Failures ..................................................................................................40
6 Trial Treatments ................................................................................41
6.1 Trial Treatments Administered .........................................................................41
6.1.1 Digital Therapeutic .........................................................................................41
[IP_ADDRESS] Call Center ..................................................................................................42
6.1.2 Antidepressant Therapy..................................................................................43Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
2
Protocol No. 345-201-[ZIP_CODE]
3
Confidential - Proprietary Information Approval: [ADDRESS_1184496] Nonconformance .....44
[IP_ADDRESS] Eliciting and Reporting Product Quality Complaints and Product 
Nonconformance.........................................................................................44
[IP_ADDRESS] Information Required for Reporting Purposes............................................45
[IP_ADDRESS] Return Process.............................................................................................45
[IP_ADDRESS] Assessment/Evaluation ...............................................................................45
6.3 Measures to Minimize/Avoid Bias....................................................................[ADDRESS_1184497] to Follow-up..........................................................54
8 Trial Procedures.................................................................................55
8.1 Efficacy Assessments........................................................................................59
8.1.1 Montgomery-Asberg Depression Rating Scale ..............................................59
8.1.2 Generalized Anxiety Disorder-7.....................................................................60
8.1.3 Clinical Global Impressions-Severity.............................................................60
8.1.4 Patient Health Questionnaire-9.......................................................................60Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
3
Protocol No. 345-201-[ZIP_CODE]
4
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE].1.5 World Health Organization Disability Assessment Schedule 2.0 ..................60
8.2 Safety Assessments ...........................................................................................61
8.2.1 Clinical Laboratory Assessments ...................................................................618.2.2 Suicidality Monitoring....................................................................................[IP_ADDRESS] Columbia-Suicide Severity Rating Scale....................................................628.3 Adverse Events..................................................................................................628.3.1 Definitions ......................................................................................................628.3.2 Eliciting and Reporting Adverse Events.........................................................[IP_ADDRESS] Anticipated Adverse Events........................................................................[IP_ADDRESS] Device Malfunction.....................................................................................[IP_ADDRESS] Unanticipated Adverse Device Effects .......................................................[IP_ADDRESS] Immediately Reportable Events ..................................................................658.3.3 Procedure for Breaking the Blind...................................................................668.3.4 Follow-up of Adverse Events .........................................................................[IP_ADDRESS] Follow-up of Nonserious Adverse Events ..................................................[IP_ADDRESS] Follow-up of Immediately Reportable Events ............................................[IP_ADDRESS] Follow-up and Reporting of Immediately Reportable Events 
Occurring After Last Scheduled Contact ....................................................[ADDRESS_1184498]................................................................................................69
9 Statistical Considerations ..................................................................70
9.1 Sample Size .......................................................................................................709.2 Datasets for Analysis.........................................................................................709.3 Handling of Missing Data for Primary and Secondary Endpoint Analysis ......719.4 Statistical Analyses ...........................................................................................71&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
Protocol No. 345-201-[ZIP_CODE]
5
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE].4.1 Efficacy Analyses ...........................................................................................71
[IP_ADDRESS] Primary Efficacy Endpoint Analysis...........................................................[IP_ADDRESS].1 Primary Estimand ....................................................................................[IP_ADDRESS].2 Primary Analysis Method........................................................................[IP_ADDRESS] Analyses on Key Secondary Efficacy Endpoint and Other/Additional 
Efficacy Endpoints......................................................................................74
[IP_ADDRESS].1 Key Secondary Efficacy Endpoint Analysis ...........................................[IP_ADDRESS].2 Efficacy Endpoints for Assessment of Durability ...................................[IP_ADDRESS].3 Other Efficacy Endpoints Analyses.........................................................[IP_ADDRESS] Control of Experiment-wise Type 1 Error ..................................................[IP_ADDRESS] Other Exploratory Endpoint Analysis.........................................................[IP_ADDRESS] Sensitivity Analyses....................................................................................779.4.2 Safety Analysis ...............................................................................................[IP_ADDRESS] Adverse Events ...........................................................................................[IP_ADDRESS] Clinical Laboratory Data.............................................................................[IP_ADDRESS] Other Safety Data........................................................................................789.4.3 Other Analyses................................................................................................[IP_ADDRESS] Analysis of Demographic and Baseline Characteristics .............................78
9.5 Interim Analysis and Adaptive Design .............................................................78
9.5.1 Data Monitoring Committee...........................................................................79
10 Supporting Documentation and Operational Considerations .......80
10.1 Appendix 1: Regulatory, Ethical, and Trial Oversight Considerations.............8010.1.1 Ethics and Responsibility ...............................................................................8010.1.2 Informed Consent ...........................................................................................8010.1.3 Confidentiality ................................................................................................8110.1.4 Quality Control and Quality Assurance..........................................................8210.1.4.1 Monitoring ..................................................................................................8210.1.4.2 Auditing ......................................................................................................8210.1.5 Protocol Deviations ........................................................................................8210.1.6 Records Management .....................................................................................8210.1.6.1 Source Documents ......................................................................................8210.1.6.2 Data Collection ...........................................................................................83&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
6
Confidential - Proprietary Information Approval: 03 Nov 202110.1.6.3 File Management at the Trial Site...............................................................84
[IP_ADDRESS] Records Retention at the Trial Site .............................................................8410.1.6.5 Publication Authorship Requirements ........................................................8410.2 Appendix 2: Urine Drugs-of-Abuse Screen ......................................................8610.3 Appendix 3: Contraceptive Guidance and Collection of Pregnancy 
Information........................................................................................................87
10.4 Appendix 4: Tokenization.................................................................................8810.4.1 Process and Methodology...............................................................................8810.4.2 Withdrawal of Subjects from Tokenization....................................................8910.5 Appendix 5: Abbreviations ...............................................................................9010.6 Appendix 6: Protocol Amendments ..................................................................92
[IP_ADDRESS] Protocol Amendment 2 ...............................................................................96
11 References ...........................................................................................98&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
7
Confidential - Proprietary Information Approval: [ADDRESS_1184499] of In-text Tables
Table 1.3-1 Schedule of Assessments...............................................................23
Table 3-1 Trial Objectives and Endpoints .....................................................31Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
7
Protocol No. 345-201-[ZIP_CODE]
8
Confidential - Proprietary Information Approval: [ADDRESS_1184500] of In-text Figures
Figure 1.2-1 Trial Design Schematic..................................................................21Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
8
Protocol No. 345-201-[ZIP_CODE]
9
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE] Protocol Summary
1.1 Synopsis
Name [CONTACT_790]: Otsuka Pharmaceutical Development & Commercialization, Inc.
Name [CONTACT_851982]: CT-152
Protocol No.: 345-201-[ZIP_CODE]
Protocol Title: A Multi-center, Randomized, Controlled Trial to Evaluate the 
Effectiveness of a Digital Therapeutic (CT-152) as Adjunctive Therapy in Adult Subjects 
Diagnosed with Major Depressive Disorder (MDD)
Protocol Lay Person Short Title: Trial to Evaluate the Effectiveness of a Digital 
Therapeutic (CT-152) as Adjunctive Therapy in Adult Subjects Diagnosed with MDD
Clinical Phase/Trial Type: Pi[INVESTIGATOR_851912]/Indication: Major depressive disorder in adults
Objectives and Endpoints:
The objectives and endpoints are provided in table below.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
9
Protocol No. 345-201-[ZIP_CODE]
10
Confidential - Proprietary Information Approval: 03 Nov 2021Objectives Endpoints
Primary objective: To compare the effectiveness 
of CT-152 with sham, in adult subjects diagnosed with MDD who are on ADT monotherapy.Primary efficacy endpoint: Change from baseline to Week [ADDRESS_1184501] will include 
3 MADRS assessments at Weeks 6, 8, and 10.  
 
 
 
 
Key secondary efficacy endpoint:
â€¢Change from baseline to Week [ADDRESS_1184502]-152 compared to sham.
Other efficacy endpoints:
â€¢Change from baseline to Weeks 2 and 4 
in the MADRS total score
â€¢Change from baseline to Weeks 2 and 4 
in the GAD-7 total score
â€¢MADRS response rate ( â‰¥ 50% 
reduction from baseline) at Weeks 2, 4, and 6.
â€¢Change from baseline to Weeks 2, 4, 
and 6 in the CGI-S score.
â€¢Change from baseline to Week 6 in the 
WHODAS 2.0 total score.
â€¢Change from screening to Weeks 4 and 
6 in the PHQ-9 total score.
â€¢MADRS partial response (MADRS 
score reduction from baseline â‰¥ 30% 
and < 50%) at Weeks 2, 4, and 6.
â€¢MADRS response rate (full or partial, 
defined as â‰¥ 30% reduction in MADRS 
total score from baseline) at Weeks 8 and 10.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
11
Confidential - Proprietary Information Approval: 03 Nov 2021Objectives Endpoints
 
 
 
Safety objective: To evaluate the safety of CT-152 in adult subjects diagnosed with MDD who are on ADT monotherapy.Safety endpoints:
â€¢Frequency and severity of AEs, serious 
AEs, and discontinuations from the trial due to AEs.
Note: The sham is a control that deploys only a working memory exercise.AE = adverse event; ADT = antidepressant therapy; CGI-S = Clinical Global Impressions-Severity; 
; GAD-7 = Generalized Anxiety Disorder-7; 
 MADRS = Montgomery-Asberg Depression Rating Scale; 
; PHQ-9 = Patient Health Questionnaire-9; 
WHODAS = World Health Organization Disability Assessment Schedule.
Trial Design:
This is a multi-center, randomized, controlled trial to evaluate the effectiveness of 
CT-152 in adult subjects diagnosed with MDD who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.
Subjects will participate in the trial for up to 13 weeks. The trial will include a screening 
period of up to 3 weeks, a treatment period for 6 weeks, and an extension period for 4 weeks.
Eligible subjects will be randomized to 1 of 2 digital mobile applications (CT-152 or 
sham) on Day 1.
To mitigate subject expectation, subjects in this trial will be blinded to the efficacy 
hypothesis. Eligible subjects will be informed by [CONTACT_851928] a) they will participate in the trial for up to 13 weeks and will be randomized to one of two digital therapeutic treatments and b) the purpose of the trial is to compare the effectiveness of the two digital therapeutic treatments when used in addition to ADT. Both treatment arms will be presented as possibly helpi[INVESTIGATOR_851913]. No references to CT-[ADDRESS_1184503]â€™s participation in the trial, and after all final visit procedures have been completed, trial site staff will inform the subject of the trial hypothesis, ie, that one digital therapeutic was hypothesized to be more beneficial in improving depression symptoms, but there was a need for a trial to confirm. &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
CCICCI
Protocol No. 345-201-[ZIP_CODE]
12
Confidential - Proprietary Information Approval: [ADDRESS_1184504] an unscheduled visit in person or remotely at any time if needed to assess a safety issue/concern.
Remote visits will be conducted using a sponsor-designated telemedicine platform with a 
portal accessible by [CONTACT_310623], and subjects will be asked to download a mobile 
application (separate from the investigational digital mobile application) in order to 
provide consent to the trial and complete trial assessments, including self-administered 
scales.
Prior to downloading the mobile application for conducting telemedicine visits, subjects 
will be asked to provide consent to participate in a registry and agree to its privacy policy and terms of service required to collect subjectsâ€™ information within the telemedicine 
platform, including identity verification. Subjects will be required to complete the 
identity verification process remotely before they can electronically sign the trial consent in order to comply with 21 Code of Federal Regulations (CFR) Part [ADDRESS_1184505]â€™s understanding of, 
and interest in, the trial will be demonstrated through adequate adherence to onboarding requirements. This will be assessed by [CONTACT_851929] 3-week screening window.
Following the screening visit, subjects will be considered eligible based upon the 
following:
â€¢Adherence and performance on the onboarding software module by [CONTACT_423] 
 
 
â€¢Continuing to meet all inclusion and no exclusion criteria based on investigator 
assessment.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCICCI
Protocol No. 345-201-[ZIP_CODE]
13
Confidential - Proprietary Information Approval: 03 Nov 2021On Day 1, the eligible subjects will be randomized 1:1 (CT-152 or sham) across 
approximately 50 trial sites. The sample size at any single trial site will be capped at approximately 15% of the total subjects randomized into the trial. Randomization will be stratified by [CONTACT_121562].
During the treatment period (Day 1 [baseline] to Week 6) subjects will have a remote 
visit at Weeks 2, 4, and 6 and will be contact[CONTACT_851930] 1, 3, and 5. Subjects will be expected to be adherent with their digital mobile application exercises during the treatment period.
After Week 6, subjects will continue participation in the trial during the extension period 
(Weeks 7 to 10). In the extension period, the digital mobile applications will remain installed for each group. Subjects will receive brief short message service (SMS) messages reminding subjects of the previously completed CT-152 or sham treatment courses (see the â€œTrial Treatmentâ€ section below for further details), and will continue their ADT. Subjects will have a remote visit at Weeks [ADDRESS_1184506] the Montgomery-Asberg Depression Rating Scale (MADRS) remotely by [CONTACT_851931]. This may occur separately from the remote trial site visit but must be 
performed within the window described in the schedule of assessments.
The Clinical Global Impressions-Severity (CGI-S) scale will be completed by [CONTACT_851932]. Other assessments to 
be performed during the trial include the Generalized Anxiety Disorder-7 (GAD-7), 
World Health Organization Disability Assessment Schedule (WHODAS) 2.0, Patient Health Questionnaire-9 (PHQ-9),  
During the trial, the trial site staff will also administer the Columbia-Suicide Severity 
Rating Scale (C-SSRS), review subject adherence to the treatment sessions during the treatment period, confirm subject adherence to their current ADT, and assess adverse events (AEs) and concomitant medications.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
14
Confidential - Proprietary Information Approval: 03 Nov 2021Trial Population:
The trial will enroll male or female subjects aged 22 to 64 years old at the time of 
informed consent, with a current primary diagnosis of MDD based on the criteria in the 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), single or 
recurrent epi[INVESTIGATOR_1865], without psychotic features and do not meet criteria for MDD with 
mixed features subtype, and who are on ADT monotherapy. If other allowable psychiatric 
diagnoses are present, they must not be considered primary (causing a higher degree of 
distress or impairment than MDD).
Key Inclusion/Exclusion Criteria:
In addition to the criteria mentioned under Trial Population above, key inclusion criteria 
are as follows:
ï‚·Subjects must be in a current major depressive epi[INVESTIGATOR_1865], as defined by [CONTACT_2681]-5 criteria 
and confirmed by [CONTACT_851933] (M.I.N.I) 
and an adequate clinical psychiatric evaluation.
ï‚·A score of Hamilton Rating Scale for Depression, 17-item (HAM-D 17) â‰¥ 18 at 
screening and the baseline visit (Day 1).
ï‚·Subject must have a reported history for the current epi[INVESTIGATOR_851914]. Treatment with the current ADT must be of 
adequate dose and duration, defined as at least 6 weeks at a minimum therapeutic 
dose (or higher) according to the [LOCATION_005] General Hospi[INVESTIGATOR_307] - Antidepressant 
Treatment Response Questionnaire (MGH-ATRQ) performed at screening. 
Inadequate response is defined as < 50% reduction in depression symptom severity 
per the MGH-ATRQ. Additionally, the subject must be on a stable dose of their 
current monotherapy ADT for a minimum of 4 weeks prior to baseline (Day 1).
ï‚·Subjects who are willing to maintain ADT treatment at current dose for the duration 
of their participation in the trial.
ï‚·Subjects who are the only users of an iPhone with iPhone operating system 
(iOS) 13.0 or greater capabilities, or a smartphone with an Android operating system 
(OS) 9.0 or greater capabilities, and agree to download and use the digital mobile 
application as required by [CONTACT_760].
ï‚·Subjects who, in the opi[INVESTIGATOR_871], will not require additional 
pharmacological intervention during the trial for the treatment of depression.
ï‚·Subjects who have successfully completed the onboarding software module in the 
digital mobile application during the screening period.
ï‚·Subjects who continue to consent to participate in the trial and are judged to 
understand the use of the digital mobile application at the baseline visit (Day 1).Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
14
Protocol No. 345-201-[ZIP_CODE]
15
Confidential - Proprietary Information Approval: 03 Nov 2021Key exclusion criteria are as follows:
ï‚·Subjects with a reported inadequate response to > [ADDRESS_1184507] 6 weeks at a minimum 
therapeutic dose (or higher) according to the MGH-ATRQ. Inadequate response is 
defined as < 50% reduction in depression symptom severity per the MGH-ATRQ.
ï‚·Subjects who have been treated with psychopharmacological augmentation for 
depression in the past or in the current epi[INVESTIGATOR_1865] (eg, lithium, triiodothyronine, or 
antipsychotics added to ADT, multiple ADTs). If, in the clinical opi[INVESTIGATOR_1070], the subject did not receive an adequate trial of an agent used for 
augmentation, these subjects may be considered for inclusion following discussion 
and approval by [CONTACT_7195].
ï‚·Subjects who are currently receiving or have received psychotherapy within 90 days 
prior to screening.
ï‚·Subjects who have failed to respond to an adequate course (â‰¥ 8 weeks) of cognitive 
behavioral therapy at any time in the past.
ï‚·Suicidality assessment:
ï‚·Subjects who answer â€œYesâ€ on the C-SSRS Suicidal Ideation Item 4 (Active 
Suicidal Ideation with Some Intent to Act, Without Specific Plan) within the last 
12 months prior to screening or at the baseline visit (Day 1), OR 
ï‚·Subjects who answer â€œYesâ€ on the C-SSRS Suicidal Ideation Item 5 (Active 
Suicidal Ideation with Specific Plan and Intent) within the last 12 months prior to 
screening or at the baseline visit (Day 1), OR
ï‚·Subjects who answer â€œYesâ€ on any of the 5 C-SSRS Suicidal Behavior Items 
(actual attempt, interrupted attempt, aborted attempt, preparatory acts, or suicidal 
behavior) within the last 24 months prior to screening or at the baseline visit 
(Day 1), OR
ï‚·Subjects who, in the opi[INVESTIGATOR_871], present a serious risk of suicide. 
ï‚·Subjects who at any time in the past have been treated with electroconvulsive therapy 
or neuro-modulation devices (transcranial magnetic stimulation, vagus nerve 
stimulation, or transcranial direct current stimulation, etc) for depression.
ï‚·Subjects who at any time in the past have received ketamine, esketamine, or 
arketamine for treatment of depression.
ï‚·Subjects who are currently using a computer, web, or smartphone software-based 
application or equivalent for mental health or depression. Subjects who agree to 
discontinue use at screening will be permitted to enter the trial.
ï‚·Subjects who have a current diagnosis of substance or alcohol use disorder (excluding 
nicotine) per DSM-5 within 6 months prior to the screening visit.
ï‚·Subjects in a current major depressive epi[INVESTIGATOR_54358] 2 years.
ï‚·Subjects who are considered resistant/refractory to treatment by [CONTACT_851934].Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
15
Protocol No. 345-201-[ZIP_CODE]
16
Confidential - Proprietary Information Approval: 03 Nov 2021ï‚·A lifetime diagnosis of schizophrenia, schizoaffective disorder, other psychotic 
disorder, or Bipolar I/II disorder, or current posttraumatic stress disorder, panic 
disorder, or obsessive-compulsive disorder, as assessed by [CONTACT_941] M.I.N.I.
ï‚·Current generalized anxiety disorder or social anxiety disorder as assessed by [CONTACT_941] 
M.I.N.I and considered to be primary (causing a higher degree of distress or 
impairment than MDD).
ï‚·Subjects diagnosed with any DSM-5 personality disorder as assessed by [CONTACT_851935]/or from medical records.
ï‚·Depression due to a general medical condition or a neurologic disorder.
ï‚·History of seizure disorder other than a single childhood febrile seizure that fully 
resolved.
ï‚·Subjects who would be likely to require prohibited concomitant therapy during the 
trial.
Trial Site(s): This trial will be conducted at approximately 50 trial sites in the United 
States.
Trial Treatment, Treatment Duration, Mode of Administration:
Subjects that meet all the initial inclusion criteria and none of the exclusion criteria at 
screening will download and install the digital mobile application onto their own 
smartphone device that they will use for the trial. A dedicated call center can assist with 
the initial downloading of and access to the digital mobile application. The investigator 
will confirm the subjectâ€™s understanding of, and interest in, the trial through adequate 
adherence to run-in onboarding requirements in the onboarding software module within a 
span of 7 consecutive days during the 3-week screening period (Day âˆ’21 to Day âˆ’1).
The onboarding software module will provide example cognitive control task sessions. 
The content of these example sessions will not include therapeutic content, so as to 
minimize bias once subjects are randomized to 1 of the 2 arms (CT-152 or sham).
At the baseline visit (Day 1), successful use of the onboarding software module will be 
confirmed. CT-[ADDRESS_1184508] of an Emotional Faces Memory Task (EFMT) 
exercise and a psychotherapy lesson. Sham will serve as a control.
Sham will provide a cognitive training exercise designed to retain user interest while 
minimizing any therapeutic effect. Each treatment session will consist of a Shapes Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
16
Protocol No. 345-201-[ZIP_CODE]
17
Confidential - Proprietary Information Approval: 03 Nov 2021Memory Task (SMT) exercise. It will present users with an analogous structure, matched 
for time and attention to the cognitive-emotional training exercise found in CT-152. In 
order to retain the intended placebo nature of the sham, it will not include EFMT or 
psychotherapy content. 
Subjects will participate in the trial for up to 13 weeks. This includes a screening period 
of up to 3 weeks; due to the onboarding adherence requirement, a minimum of 
7 consecutive days will be required for screening. Extensions to the screening period, if 
requested by [CONTACT_093], may be granted after discussion and approval by [CONTACT_35041].
The intervention will begin the same day as the baseline visit, once the baseline visit has 
been completed. The subjects will progress through a treatment schedule of 18 sessions 
(approximately 30 - 45 minutes) at a rate of 3 sessions per week over the 6-week 
treatment period (Day 1 [baseline] to Week 6).
After Week 6, subjects will continue participation in the trial during the extension period 
(Weeks 7 to 10). In the extension period, the digital mobile applications will remain 
installed for each group with EFMT and SMT no longer available. Psychotherapy content 
provided previously will remain available for optional reference in the CT-[ADDRESS_1184509] contacts the call center with an AE, the call center will log the call and will 
immediately provide this information to the trial site and sponsor or sponsorâ€™s designee 
for follow-up.
If a subject contacts the call center with a possible or suspected product quality complaint 
(PQC), the call center will log the call. All call records (tickets) captured by [CONTACT_851936], 
tracking, and resolution.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
17
Protocol No. 345-201-[ZIP_CODE]
18
Confidential - Proprietary Information Approval: [ADDRESS_1184510] information and processes are detailed in the Site 
Operations Manual.
Trial Assessments:
Assessments for Efficacy: MADRS, GAD-7, CGI-S, WHODAS 2.0, and PHQ-9.Assessments for Safety: AEs (including AEs related to the worsening of depressive 
symptoms) and C-SSRS.
Screening/Other:  M.I.N.I, HAM-D
17, 
Antidepressant Treatment Response Questionnaire, DSM-[ADDRESS_1184511], and adherence check.
Data Monitoring Committee:
A Data Monitoring Committee (DMC) will be chartered for this trial. The DMC will 
include at least [ADDRESS_1184512] expertise in MDD treatment trials. The DMC will be convened at intervals described in the DMC charter to review data on recruitment, retention, interim analysis, and safety (including evaluation of discontinuation criteria), and to review data for completeness and quality during the trial. Discontinuation criteria will be prespecified and included in the DMC charter.
Statistical Methods:The initial sample size is calculated to detect a 3-unit difference between CT-152+ADT 
and sham+ADT in the change from baseline in MADRS total score with 85% power at a 2-sided Î± = 0.[ADDRESS_1184513] deviation of 9. The resulting sample 
size is 324 evaluable subjects in total (162 subjects in each arm). To compensate for subjects that fail to have evaluable assessments of MADRS total score in the full analysis set (FAS) sample (estimated at up to 10% of all subjects), a total of 360 subjects (180 subjects in each arm) will be randomized in this trial.
Due to the limitations of applying assumptions on the treatment effect size, and in order 
to ensure adequate power of the trial, an unblinded interim analysis will be conducted by &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
19
Confidential - Proprietary Information Approval: 03 Nov 2021a DMC. The final sample size could be increased to 540 subjects (270 subjects in each 
arm) as per recommendation of the DMC. Using the Oâ€™Brien-Fleming spending function, a significance level of 0.003 (2-sided) is allocated to this interim analysis. The corresponding final significance level is 0.049 (2-sided).
The null hypothesis of the statistical test comparing CT-152+ADT and sham+ADT, 
based on the primary efficacy endpoint, is that the change in MADRS using 
CT-152+ADT is equal to the change in MADRS using the sham+ADT.
The primary analysis will be conducted on the change from baseline in MADRS total 
score to the final on-therapy evaluation (Week 6) based on the FAS sample adjusted for the baseline MADRS total score.
 
. In this trial, we plan to detect a 3-point difference on the primary 
efficacy endpoint between the treatment groups.  
 This trial is considered positive if the trial will be stopped at the 
interim analysis for efficacy, or if the p-value of the statistical comparison based on the 
primary efficacy endpoint at final is < 0.049.
The primary analysis will utilize mixed model repeated measurements (MMRM) with 
treatment, visit, treatment by [CONTACT_23259], and site as fixed effects to assess heterogeneity of treatment effects. The key secondary efficacy endpoint and other efficacy endpoints will be analyzed based on the FAS as described for the primary analysis.
The null hypothesis of the statistical test comparing CT-152+ADT and sham+ADT, 
based on the key secondary efficacy endpoint, is that the change from baseline to Week [ADDRESS_1184514]-152+ADT is equal to the change from baseline to Week 6 in the GAD-7 total score using sham+ADT.
The key secondary efficacy endpoint will be analyzed using the same method (MMRM) 
as in the primary analysis with a replacement of the interaction term of visit by [CONTACT_851937]-[ADDRESS_1184515] either completed the Week 6 visit or discontinued prior to Week 6. &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
Protocol No. 345-201-[ZIP_CODE]
20
Confidential - Proprietary Information Approval: [ADDRESS_1184516] size, possibly combined with 
other external information, without inflating the type I error.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
20
Protocol No. 345-201-[ZIP_CODE]
21
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE].2 Schema
Figure 1.2-1 Trial Design Schematic
ADT = antidepressant therapy.
Note: All visits will be performed remotely. The screening visit may be performed in person at the discretion of the investigat or.
aThe subjectâ€™s understanding of, and interest in, the trial will be demonstrated through adequate adherence to onboarding requir ements. This will be assessed by [CONTACT_851938] 3-week screening 
window.Screening
Days âˆ’21 to âˆ’1aTreatment Period
6 weeks
ScreeningPopulation: 
Subjects 
diagnosed with major depressive disorder who are on ADT monotherapy
Remote visits at Weeks 2, 4, and 6c
Telephone contact [CONTACT_328548] 1, 3, and 5
Efficacy and safety assessments.
Baseline
Day 1Randomization
Up to 540 subjects 
(270 subjects in 
each arm)bCT-152 + ADT
Sham + ADTExtension Period
[ADDRESS_1184517]-152 + ADT
Remote visits at Weeks [ADDRESS_1184518] and safety assessments.
Week 6 Week 10Sham + ADT&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
22
Confidential - Proprietary Information Approval: 03 Nov 2021bThe initial sample size is 360 subjects randomized in total. The final sample size could be increased to 540 subjects (270 subjects in each arm) as per 
recommendation of the Data Monitoring Committee.
cIf deemed necessary by [CONTACT_093], additional evaluations may also be performed at an unscheduled visit either remotely or in person.
dAfter Week 6, subjects will continue participation in the trial during the extension period (Weeks 7 to 10). In the extension period, the digital mobile applications will 
remain installed for each group. Subjects will receive brief SMS messages reminding subjects of the previously completed CT-152 or sham treatment courses, and 
will continue their ADT.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
22
Protocol No. 345-201-[ZIP_CODE]
23
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE].3 Schedule of Assessments
Table 1.3-1 Schedule of Assessments
Period Screeninga Treatment Period Extension Periodb
Trial Day
(Week)Day âˆ’21 to 
Day âˆ’1Day 1
(Baseline)Day
7
W1Day 
14
W2Day 
21
W3Day 
28
W4Day 
35
W5Day 
42
W6Day
49
W7Day
56
W8Day
63
W9Day
70
W10cNotes
Remote visit via 
telemedicine 
technologyd, eXa X X X Xf X Xg
Telephone 
contactd X X X X X
ENTRANCE/HISTORY
Informed consent Xh Section 10.1.2
Demographics 
and medical 
historyX Section 8
Psychiatric 
history and 
diagnosisX Section 8
Substance usage 
history and 
alcohol use 
disorders historyXSection 8
Section 8.4.7
DSM-5 diagnosis 
of MDD XSection 8
Section 8.4.6
M.I.N.I X Section 8.4.3
Eligibility criteria X XSection 5.2
Section 8Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
23
Protocol No. 345-201-[ZIP_CODE]
24
Confidential - Proprietary Information Approval: 03 Nov 2021Table 1.3-1 Schedule of Assessments
Period Screeninga Treatment Period Extension Periodb
Trial Day
(Week)Day âˆ’21 to 
Day âˆ’1Day 1
(Baseline)Day
7
W1Day 
14
W2Day 
21
W3Day 
28
W4Day 
35
W5Day 
42
W6Day
49
W7Day
56
W8Day
63
W9Day
70
W10cNotes
 
 
Confirm ADT use
i XX XX XX XX XX XXSection 6.1.2
Section 6.5
ATRQ XSection 8
Section 8.4.4
HAM-D 17XX Section 8.4.5
Randomization X Section 5.1
EFFICACY
MADRS 
(independent rater)X
X X X X X Section 8.1.1
CGI-S X X X X Section 8.1.3
PHQ-9 X X X Section 8.1.4
GAD-7 X X X X X X Section 8.1.2
WHODAS 2.0 X X Section 8.1.5
 &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCICCICCI
CCI CCI
Protocol No. 345-201-[ZIP_CODE]
25
Confidential - Proprietary Information Approval: 03 Nov 2021Table 1.3-1 Schedule of Assessments
Peri
od Screeninga Treatment Pe
riod Extension Periodb
Trial Day
(Week)Day âˆ’21 to 
Day âˆ’1Day 1
(Baseline)Day
7
W1Day 
14
W2Day 
21
W3Day 
28
W4Day 
35
W5Day 
42
W6Day
49
W7Day
56
W8Day
63
W9Day
70
W10cNotes
SAFETY
Adverse eventsj X X X X X X X X X X X X Section 8.3
C-SSRS X X X X X X X Section [IP_ADDRESS]
Prior/concomitant 
therapyX X X X X X X X X X X XSection [ADDRESS_1184519] XSection 8.4.8
Section 10.3
Adherence check 
(use of digital 
mobile 
application)X X X X X Section 6.[ADDRESS_1184520] 
debriefingk XSection 6.3
Section 8Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
25
Protocol No. 345-201-[ZIP_CODE]
26
Confidential - Proprietary Information Approval: 03 Nov 2021ADT = antidepressant therapy; ATRQ = Antidepressant Treatment Response Questionnaire; CGI-S = Clinical Global Impressions-Sever ity; 
C-SSRS = Columbia-Suicide Severity Rating Scale; ; DSM-5  = Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition; ; GAD-7 = Generalized Anxiety Disorder-7; HAM-D 17 = Hamilton Rating Scale for 
Depression, 17-item; ; MADRS = Montgomery-Asberg Depression Rating Scale; M.I.N.I = Mini International Neuropsychiatric Interview; PHQ-9 = Patient Health Questionnaire-9; W = week; WHODAS = World Health Organization Disability Ass essment 
Schedule.
Note: Shaded cells indicate trial days that subjects will be contact[CONTACT_851939].
aThe subjectâ€™s understanding of, and interest in, the trial will be demonstrated through adequate adherence to onboarding requir ements.  
 
The screening visit may be performed in person at the discretion of the investigator.
bAfter Week 6, subjects will continue participation in the trial during the extension period (Weeks 7 to 10). In the extension p eriod, the digital mobile 
applications will remain installed for each group. Subjects will receive brief SMS messages reminding subjects of the previousl y completed CT-[ADDRESS_1184521] a Â± [ADDRESS_1184522] schedules and 
for weekends.
eIf deemed necessary by [CONTACT_093], additional evaluations may also be performed at an unscheduled visit either remotely o r in person.
fFor subjects who discontinue early before Week 6, the procedures designated for Day 42 (including subject debriefing) will be o btained at an early 
termination visit occurring as soon as possible after the last use of CT-[ADDRESS_1184523]â€™s participation in the trial and after all final visit procedures have been completed .&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCICCI
CCICCI
Protocol No. 345-201-[ZIP_CODE]
27
Confidential - Proprietary Information Approval: [ADDRESS_1184524]-152 is a prescription digital therapeutic intended for the treatment of major depressive 
disorder (MDD) in adults. It is intended for use as an adjunct to standard of care 
(pharmacotherapy) and under the supervision of a clinician. The current trial is designed 
to provide data regarding effectiveness and safety for CT-152.
CT-152 is being co-developed by [CONTACT_35093] & 
Commercialization, Inc. and Click Therapeutics, Inc.
This trial will evaluate the effectiveness of CT-152 in reducing depressive symptoms in 
adult subjects diagnosed with MDD who are on antidepressant therapy (ADT) 
monotherapy. CT-[ADDRESS_1184525]-152 may be considered a novel, psychiatric digital 
therapeutic option for patients diagnosed with MDD.
2.2 Background
A 2017 World Health Organization publication Depression and Other Common Mental 
Disorders: Global Health Estimates reported 322 million people across the globe, 4.4% 
of the worldâ€™s population, are living with depression.1 In a large  2018 [LOCATION_002] (US) 
national survey, prevalence estimates for Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5) MDD were even higher with 12-month and lifetime 
prevalence of MDD reported at 10.4% and 20.6%, respectively, with most having 
moderate (6 - 7 symptoms) or severe (8 - 9 symptoms) MDD that was associated with 
comorbidity and impairment.[ADDRESS_1184526] due 
to disability.4 Based on data  from 2010, depression-related expenditures in the US were Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
27
Protocol No. 345-201-[ZIP_CODE]
28
Confidential - Proprietary Information Approval: 03 Nov 2021greater than $210 billion, with employers incurring $[ADDRESS_1184527] medical costs of $99 billion.5 There 
is a critical need to improve treatment outcomes associated with major depression.6
Major depressive di sorder, per DSM-5, is defined by 5 criteria: (A) the presence of 
â‰¥ 5 symptoms to be present within a 2-week period, (B) The symptoms cause clinically 
significant distress or impairment in social, occupational, or other important areas of 
functioning, (C) The epi[INVESTIGATOR_238196] a substance 
or to another medical condition, (D) The occurrence of a major depressive epi[INVESTIGATOR_1865] 
(MDE) is not better explained by [CONTACT_238261], schizophrenia, 
schizophreniform disorder, delusional disorder, or other specified and unspecified 
schizophrenia spectrum and other psychotic disorders and (E) There has never been a 
manic epi[INVESTIGATOR_17114] a hypomanic epi[INVESTIGATOR_1865].7
Criteri a A to C above represent a MDE.7 Primary symptom s of MDE are depressed mood 
or anhedonia (loss of interest or pleasure), while secondary symptoms of MDE include 
appetite or weight changes, sleep difficulties (insomnia or hypersomnia), psychomotor 
agitation or retardation, fatigue or loss of energy, diminished ability to think or 
concentrate, feelings of worthlessness or excessive guilt, and suicidality.7 Each sympt om 
is rated in all or none (1 or 0), with the total symptom score determining the presence (or 
the absence) of MDE.[ADDRESS_1184528] from 
various treatment modalities treatment in the acute phase to target remission of the MDE 
and return the patient to the level of functioning prior to the MDE.10 Currently a vailable 
options include ADT, depression-focused psychotherapy (eg, cognitive behavioral 
therapy [CBT]), ADT and psychotherapy combination treatment, or other somatic 
therapi[INVESTIGATOR_014] (eg, electroconvulsive therapy (ECT), transcranial magnetic stimulation).10 
Clinical features (eg, symptom severity, presence of co-occurring disorders or 
psychosocial stressors) and other factors (eg, patient preference, prior treatment 
experiences) influence clinician selection of an initial treatment modality.[ADDRESS_1184529] sustained response.11,12 Combinat ion therapy also appears to provide significantly 
higher improvements in depression symptoms, improvement in quality of life, and 
increased compliance with treatment.13Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
28
Protocol No. 345-201-[ZIP_CODE]
29
Confidential - Proprietary Information Approval: 03 Nov 2021Despi[INVESTIGATOR_851915], unmet needs remain in the 
treatment of MDD. Firstly, many patients with MDD do not receive adequate treatment 
due to a variety of barriers (eg, shortage and uneven geographic distribution of trained 
providers10,14,15,16 time gaps seeing a provider17 and pati ent preferences18). Secondly, 
even when patients receive adequate treatment, many have a suboptimal 
response.19,20,21,[ADDRESS_1184530]-line MDD treatments.
The digital therapeutic for evaluation in this trial includes a cognitive-emotive training 
intervention called Emotional Faces Memory Task (EFMT) which has been shown to 
reduce symptoms of depression.30,[ADDRESS_1184531]-treatment to identify changes in resting-state functional connectivity and effective 
connectivity during emotional working memory processing, provided initial evidence that 
EFMT may be associated with changes in short-term plasticity of brain networks 
implicated in MDD.35
In additi on to the aforementioned cognitive and emotional deficits, depression is 
characterized by [CONTACT_851940].36 Symptoms inc lude, but are not limited to, negative self-concept, Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
29
Protocol No. 345-201-[ZIP_CODE]
30
Confidential - Proprietary Information Approval: [ADDRESS_1184532]-152.
2.3 Known and Potential Risks and Benefits
Adverse events (AEs) related to mobile device use may include dizziness, fatigue, or 
headache. No attributable AEs were observed in previous research studying CT-152. 
Please refer to the CT-[ADDRESS_1184533]-152 is intended to help 
patients who engage with the digital therapeutic to alleviate or reduce symptoms of 
MDD.
The subjects may experience some AEs due to their underlying condition or with the use 
of ADT. The risk profile of ADTs used in clinical practice is well understood and is 
detailed in the package insert of the ADT medications.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
30
Protocol No. 345-201-[ZIP_CODE]
31
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE] Objectives and Endpoints
The trial objectives and endpoints are provided in Table 3-1 .
Table 3-1 Trial Objectives and Endpoints
Objectives Endpoints
Primary objective: To compare the effectiveness 
of CT-152 with sham, in adult subjects diagnosed with MDD who are on ADT monotherapy.Primary efficacy endpoint: Change from baseline to Week [ADDRESS_1184534] will include 
3 MADRS assessments at Weeks 6, 8, and 10.  
 
 
 
 
Key secondary efficacy endpoint:
â€¢Change from baseline to Week [ADDRESS_1184535]-152 compared to sham.
Other efficacy endpoints:
â€¢Change from baseline to Weeks 2 and 4 
in the MADRS total score
â€¢Change from baseline to Weeks 2 and 4 
in the GAD-7 total score
â€¢MADRS response rate ( â‰¥ 50% 
reduction from baseline) at Weeks 2, 4, and 6.
â€¢Change from baseline to Weeks 2, 4, 
and 6 in the CGI-S score.
â€¢Change from baseline to Week 6 in the 
WHODAS 2.0 total score.
â€¢Change from screening to Weeks 4 and 
6 in the PHQ-9 total score.
â€¢MADRS partial response (MADRS 
score reduction from baseline â‰¥ 30% 
and < 50%) at Weeks 2, 4, and 6.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
32
Confidential - Proprietary Information Approval: 03 Nov 2021Table 3-1 Trial Objectives and Endpoints
Objectives Endpoints
â€¢MADRS response rate (full or partial, 
defined as â‰¥ 30% reduction in MADRS 
total score from baseline) at Weeks 8 and 10.
 
 
 
Safety objective: To evaluate the safety of CT-152 in adult subjects diagnosed with MDD who are on ADT monotherapy. Safety endpoints:
â€¢Frequency and severity of AEs, serious 
AEs, and discontinuations from the trial due to AEs.
CGI-S = Clinical Global Impressions-Severity;  
GAD-7 = Generalized Anxiety Disorder-7; ; MADRS = Montgomery-Asberg Depression Rating Scale;  
 PHQ-9 = Patient Health Questionnaire-9; WHODAS = World Health Organization 
Disability Assessment Schedule.
Section 9.4  describes the  statistical analysis of the endpoints.
4 Trial Design
4.1 Type/Design of Trial
This is a multi-center, randomized, controlled trial to evaluate the effectiveness of 
CT-[ADDRESS_1184536]-152 in reducing 
depressive symptoms compared with sham which will serve as a control. The primary efficacy endpoint is the change from baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score. The key secondary efficacy endpoint for the trial is the change from baseline to Week 6 in the Generalized Anxiety Disorder-7 (GAD-7) total score. The other efficacy endpoints will include the evaluation of the MADRS, GAD-7, Clinical Global Impression â€“ Severity (CGI-S), World Health Organization Disability Assessment Schedule (WHODAS) 2.0, and Patient Health Questionnaire-(PHQ-9) at Weeks 2, 4, and/or 6. To evaluate the durability of the effect of CT-152, the change from baseline to in MADRS and GAD-7 total score as well as &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCICCI
CCI
Protocol No. 345-201-[ZIP_CODE]
33
Confidential - Proprietary Information Approval: 03 Nov 2021MADRS response rate will be evaluated at Weeks 8 and 10. Further details are provided 
in Table 3-1.
Subjects will participate in the trial for up to 13 weeks. The trial will include a screening 
period of up to 3 weeks, a treatment period for 6 weeks, and an extension period for 
4 weeks.
Eligible subjects will be randomized to 1 of 2 digital mobile applications (CT-152 or 
sham) on Day 1.
To mitigate subject expectation, subjects in this trial will be blinded to the efficacy 
hypothesis. Eligible subjects will be informed by [CONTACT_851928] a) they will 
participate in the trial for up to 13 weeks and will be randomized to one of two digital 
therapeutic treatments and b) the purpose of the trial is to compare the effectiveness of 
these two digital therapeutic treatments when used in addition to ADT. Both treatment 
arms will be presented as possibly helpi[INVESTIGATOR_851913]. No references to CT-[ADDRESS_1184537]â€™s participation in the 
trial, and after all final visit procedures have been completed, trial site staff will inform 
the subject of the trial hypothesis, ie, that one digital therapeutic was hypothesized to be 
more beneficial in improving depression symptoms, but there was a need for a trial to 
confirm. Trial site staff will be provided with debriefing guidelines to assist in this 
discussion with the subject. See Section 6.3 Measures to Minimi ze/Avoid Bias.
Trial site staff will implement procedures either by [CONTACT_851941], at all visits. The screening visit may be performed in person at 
the discretion of the investigator. A trial site may conduct an unscheduled visit in person 
or remotely at any time if needed to assess a safety issue/concern.
Remote visits will be conducted using a sponsor-designated telemedicine platform with a 
portal accessible by [CONTACT_310623], and subjects will be asked to download a mobile 
application (separate from the investigational digital mobile application) in order to 
provide consent to the trial and complete trial assessments, including self-administered 
scales.
Prior to downloading the mobile application for conducting telemedicine visits, subjects 
will be asked to provide consent to participate in a registry and agree to its privacy policy 
and terms of service required to collect subjectsâ€™ information within the telemedicine 
platform, including identity verification. Subjects will be required to complete the 
identity verification process remotely before they can electronically sign the trial consent 
in order to comply with 21 Code of Federal Regulations (CFR) Part 11 electronic 
signature [CONTACT_225135]. Details are found in the Site Operations Manual.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
33
Protocol No. 345-201-[ZIP_CODE]
34
Confidential - Proprietary Information Approval: [ADDRESS_1184538]â€™s understanding of, 
and interest in, the trial will be demonstrated through adequate adherence to onboarding requirements. This will be assessed by [CONTACT_851929] 3-week screening window.
Following the screening visit, subjects will be considered eligible based upon the 
following:
â€¢Adherence and performance on the onboarding software module by [CONTACT_423] 
 
â€¢Continuing to meet all inclusion and no exclusion criteria based on investigator 
assessment.
On Day 1, the eligible subjects will be randomized 1:1 (CT-152 or sham) across 
approximately 50 trial sites in the US. The sample size at any single trial site will be capped at approximately 15% of the total subjects randomized into the trial. Randomization will be stratified by [CONTACT_121562].
During the treatment period (Day 1 [baseline] to Week 6) subjects will have a remote 
visit at Weeks 2, 4, and 6 and will be contact[CONTACT_851930] 1, 3, and 5. Subjects will be expected to be adherent with their digital mobile application exercises during the treatment period.
After Week 6, subjects will continue participation in the trial during the extension period 
(Weeks 7 to 10). In the extension period, the digital mobile applications will remain installed for each group. Subjects will continue to receive brief short message service (SMS) messages reminding subjects of the previously completed CT-152 or sham treatment courses (see Section 6.1.1  for further det ails), and will continue their ADT. 
Subjects will have a remote visit at Weeks [ADDRESS_1184539], will rate &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
Protocol No. 345-201-[ZIP_CODE]
35
Confidential - Proprietary Information Approval: [ADDRESS_1184540] be performed within the window described in the schedule of assessments ( Table 1.3-1 ).
The CGI-S scale will be completed by [CONTACT_851942]. Other assessments to be performed during the trial include the GAD-7, WHODAS 2.0, PHQ-9,  
During the trial, the trial site staff will administer the Columbia-Suicide Severity Rating 
Scale (C-SSRS), review subject adherence to the treatment sessions during the treatment 
period, confirm subject adherence to their current ADT, and assess AEs and concomitant 
medications.
4.2 Scientific Rationale for Trial Design
In clinical practice the digital therapeutic is to be used in the context of prescription under 
clinical supervision by [CONTACT_851943]; thus, regular bi-weekly interactions with the trial site are scheduled, which include procedures to discuss engagement with the 
product and protocol adherence (treatment period only), AEs, and concomitant 
medications.
As the content of CT-[ADDRESS_1184541] no access to trial data or clinical information other than what is solicited for this assessment (see Section 6.3  Measures to 
Minimize/Avoid Bias for further information). Subjects will be assessed based on standard clinician-rated and subject-rated outcome scales for depression and anxiety during the treatment period. In addition, in order to minimize potential expectation effects, subjects will be informed that either one of the two randomized treatments may improve symptoms of depression.
To evaluate durability of effect, the trial will include a 4-week extension period for all 
subjects. During the extension period, subjects will continue to receive SMS messaging and will continue their ADT.
4.3 Dosing Rationale
Not applicable.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
36
Confidential - Proprietary Information Approval: [ADDRESS_1184542] identifier (ID; site number [3 digits] + subject 
number ['S' + 5 digits] upon providing consent) and the site number will be designated by [CONTACT_456].  
Subjects will be randomized into the trial on Day [ADDRESS_1184543]â€™s privacy and confidentiality. Information that could identify a subject will be masked on any material received by [CONTACT_456].
5.[ADDRESS_1184544].&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
37
Confidential - Proprietary Information Approval: [ADDRESS_1184545] eligibility should be reviewed and documented by [CONTACT_296982]â€™s trial team before subjects are included in the trial. There must be evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial prior to any trial 
procedure being performed. Subjects must be willing and able to comply with scheduled 
remote visits and telephone contacts, treatment plan, urine test for drugs-of-abuse, and other trial procedures.
Trial sites are required to communicate certain aspects of subject data during the 
screening period  as detailed in the Site Operations Manual. An assessment on inclusion and exclusion criteria will be made to determine the subjectâ€™s eligibility  approve subject eligibility in order for the subjects to be randomized. Subjects cannot be enrolled until trial site 
personnel have received the final  notification from the medical monitor or clinical 
scientist.
5.2.1 Inclusion Criteria
Subjects are required to meet the following inclusion criteria at the time points described 
in the schedule of assessments ( Table 1.3-1 ).
1) Male or female subjects aged 22 to 64 years old at the time of informed consent.
2) Fluent in written and spoken English (confirmed by [CONTACT_851944] [ICF]).
3a) A current primary diagnosis of MDD based on the criteria in the DSM-[ADDRESS_1184546] not be considered primary (causing a higher degree of distress or impairment than MDD).
3b) Subjects must be in a current MDE, as defined by [CONTACT_2681]-5  criteria and confirmed 
by [CONTACT_851933] (M.I.N.I) and an adequate clinical psychiatric evaluation.
4) A score of Hamilton Rating Scale for Depression, 17-item (HAM-D
17) â‰¥ 18 at 
screening and the baseline visit (Day 1).
5) Subjects must have a reported history for the current epi[INVESTIGATOR_851916]. Treatment with the current ADT must be of adequate dose and duration, defined as at least 6 weeks at a minimum therapeutic dose (or higher) according to the [LOCATION_005] General Hospi[INVESTIGATOR_307] - Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
 performed at 
screening. Inadequate response is defined as < 50% reduction in depression symptom severity per the MGH-ATRQ. Additionally, the subject must be on a stable dose of their current monotherapy ADT for a minimum of 4 weeks prior to baseline (Day 1).&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCICCI
CCI CCI
Protocol No. 345-201-[ZIP_CODE]
38
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE]) Subjects who are willing to maintain ADT treatment at the current dose for the 
duration of their participation in the trial.
7) Subjects and the clinician are able to confirm a calendar of remote visits and 
telephone contacts.
8) Subjects who are the only users of an iPhone with iPhone operating system 
(iOS) 13.0 or greater capabilities, or a smartphone with an Android operating 
system (OS) 9.0 or greater capabilities, and agree to download and use the digital 
mobile application as required by [CONTACT_760].
9) Subjects who are willing and able to receive SMS text messages and push 
messages on their smartphone.
10) Subjects who, in the opi[INVESTIGATOR_871], will not require additional 
pharmacological intervention during the trial for the treatment of depression.
11) Subjects who have successfully completed the onboarding software module in the 
digital mobile application during the screening period.
12) Subjects who continue to consent to participate in the trial and are judged to 
understand the use of the digital mobile application at the baseline visit (Day 1).
5.2.2 Exclusion Criteria
Subjects will be excluded if they meet any of the following exclusion criteria at the time 
points described in the schedule of assessments (Table 1.3-1).
1) Subjects who are trial site staff members or employees directly involved in the 
conduct of the trial.
2) Subjects with a reported inadequate response to > [ADDRESS_1184547] 6 weeks at a minimum 
therapeutic dose (or higher) according to the MGH-ATRQ. Inadequate response is 
defined as < 50% reduction in depression symptom severity per the MGH-ATRQ.
3) Subjects who have been treated with psychopharmacological augmentation for 
depression in the past or in the current epi[INVESTIGATOR_1865] (eg, lithium, triiodothyronine, or 
antipsychotics added to ADT, multiple ADTs). If, in the clinical opi[INVESTIGATOR_1070], the subject did not receive an adequate trial of an agent used for 
augmentation, these subjects may be considered for inclusion following 
discussion and approval by [CONTACT_7195].
4) Subjects who are currently receiving or have received psychotherapy within 
90 days prior to screening.
5)Subjects who have failed to respond to an adequate course (â‰¥ 8 weeks) of CBT at 
any time in the past.
6) Suicidality assessment:
ï‚·Subjects who answer â€œYesâ€ on the C-SSRS Suicidal Ideation Item 4 (Active 
Suicidal Ideation with Some Intent to Act, Without Specific Plan) within the 
last 12 months prior to screening or at the baseline visit (Day 1), OR Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
38
Protocol No. 345-201-[ZIP_CODE]
39
Confidential - Proprietary Information Approval: 03 Nov 2021ï‚·Subjects who answer â€œYesâ€ on the C-SSRS Suicidal Ideation Item 5 (Active 
Suicidal Ideation with Specific Plan and Intent) within the last 12 months 
prior to screening or at the baseline visit (Day 1), OR
ï‚·Subjects who answer â€œYesâ€ on any of the 5 C-SSRS Suicidal Behavior Items 
(actual attempt, interrupted attempt, aborted attempt, preparatory acts, or 
suicidal behavior) within the last 24 months prior to screening or at the 
baseline visit (Day 1), OR
ï‚·Subjects who, in the opi[INVESTIGATOR_871], presents a serious risk of 
suicide.
7) Subjects who at any time in the past have been treated with ECT or 
neuro-modulation devices (transcranial magnetic stimulation, vagus nerve 
stimulation, or transcranial direct current stimulation, etc) for depression.
8) Subjects who have at any time in the past received ketamine, esketamine, or 
arketamine for treatment of depression.
9) Subjects who are currently using a computer, web, or smartphone software-based 
application or equivalent for mental health or depression. Subjects who agree to 
discontinue use at screening will be permitted to enter the trial.
10) Subjects who have a current diagnosis of substance or alcohol use disorder 
(excluding nicotine) per DSM-5  criteria within 6 months prior to the screening 
visit.
11) Subjects with a positive urine drug screen for illicit drugs or prohibited 
medications are excluded. Subjects with a positive urine drug screen resulting 
from use of cannabis, or prescription or over-the-counter medications, or products 
that, in the investigatorâ€™s documented opi[INVESTIGATOR_1649], do not signal a clinical condition 
that would impact the safety of the subject or interpretation of the trial results may 
continue evaluation for the trial following consultation and approval by [CONTACT_35041]. Additionally, the investigator may retest the subject if it is 
believed the positive urine drug screen is a false positive test, following 
discussion with the medical monitor.
12)  Subjects in a current MDE lasting longer than 2 years.
13) Subjects who are considered resistant/refractory to treatment by [CONTACT_851934].
14) A lifetime diagnosis of schizophrenia, schizoaffective disorder, other psychotic 
disorder, or Bipolar I/II disorder, or current posttraumatic stress disorder, panic 
disorder, or obsessive-compulsive disorder, as assessed by [CONTACT_941] M.I.N.I.
15) Current generalized anxiety disorder or social anxiety disorder as assessed by [CONTACT_941] 
M.I.N.I and considered to be primary (causing a higher degree of distress or 
impairment than MDD).
16) Subjects diagnosed with any DSM-5 personality disorder as assessed by [CONTACT_851935]/or from medical records.
17) Depression due to a general medical condition or a neurologic disorder.
18) History of seizure disorder other than a single childhood febrile seizure that fully 
resolved.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
39
Protocol No. 345-201-[ZIP_CODE]
40
Confidential - Proprietary Information Approval: 03 Nov 202119) Subjects who would be likely to require prohibited concomitant therapy during 
the trial.
20) Female subjects of childbearing potential with a confirmed positive pregnancy 
test result after signing the informed consent and before the baseline visit on 
Day 1.
21) Participation in other clinical research trials (interventional or observational) 
involving investigational drugs or devices within 180 days prior to randomization 
and/or during trial participation, or who have participated in more than [ADDRESS_1184548] year.
22) Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) 
for treatment of either a psychiatric or physical (eg, infectious disease) illness.
23) Subjects who, in the opi[INVESTIGATOR_871], sponsor, or medical monitor, 
should not participate in the trial.
Subjects must agree to restrictions to medications and lifestyle as described in 
Section 6.5.[ADDRESS_1184549] from whom informed consent is obtained and is documented 
in writing (ie, subject signs an ICF), but who is not randomized or assigned trial 
treatment.
Subjects who sign an ICF but who are not randomized to CT-[ADDRESS_1184550] meets the definition 
of a screen failure in this trial, the following information will be recorded in eSource:
ï‚·Date of informed consentClinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
40
Protocol No. 345-201-[ZIP_CODE]
41
Confidential - Proprietary Information Approval: 03 Nov 2021â€¢Visit date (screening visit)
â€¢Demographics (collection date, date of birth, sex, race, ethnicity)
â€¢Result of eligibility assessment
â€¢Screen failure date
â€¢Reason for screen failure
[ADDRESS_1184551]â€™s understanding of, and interest in, the trial through adequate adherence to the run-in onboarding requirements in the onboarding software module 
 during the 3-week screening period (Day âˆ’21 to 
Day âˆ’1).
The onboarding software module will provide example cognitive control task sessions. 
The content of these example sessions will not include therapeutic content, so as to minimize bias once subjects are randomized to 1 of the 2 arms (CT-152 or sham).
At the baseline visit (Day 1), successful use of the onboarding software module will be 
confirmed. Success is defined as completing [ADDRESS_1184552] of a Shapes &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
Protocol No. 345-201-[ZIP_CODE]
42
Confidential - Proprietary Information Approval: 03 Nov 2021Memory Task (SMT) exercise. It will present users with an analogous structure, matched 
for time and attention to the cognitive-emotional training exercise found in CT-152. In 
order to retain the intended placebo nature of the sham, it will not include EFMT or 
psychotherapy content.
The intervention will begin the same day as the baseline visit, once the baseline visit has 
been completed. The subjects will progress through a treatment schedule of 18 sessions 
(approximately 30 - 45 minutes) at a rate of 3 sessions per week over the 6-week 
treatment period (Day 1 [baseline] to Week 6).
After Week 6, subjects will continue participation in the trial during the extension period 
(Weeks 7 to 10). In the extension period, the digital mobile applications will remain 
installed for each group with EFMT and SMT no longer available. Psychotherapy content 
provided previously will remain available for optional reference in the CT-[ADDRESS_1184553]-152 and sham treatment courses.
[IP_ADDRESS] Call Center
A dedicated call center is available to support the subject and the trial site on the initial 
downloading of and access to the digital mobile application, as well as any technical 
issues with the digital mobile application throughout the trial.
Subjects must be instructed by [CONTACT_851945]. All calls to the call center will be 
documented and processed. Basic user technical issues will be resolved by [CONTACT_263737].
If a subject contacts the call center with an AE, the call center will log the call and 
immediately provide this information to the trial site and sponsor or sponsorâ€™s designee 
for follow-up per Section 8.3.
If a subject contacts the call center with a possible or suspected product quality complaint 
(PQC), the call center will log the call. All call records (tickets) captured by [CONTACT_851936], 
tracking, and resolution per Section 6.2.2.
If a subject reports a possible or suspected PQC to the investigator or designee during a 
remote visit or telephone contact, the investigator or designee is to immediately contact 
[CONTACT_263737], which will log the call and immediately provide the information to the 
Click Therapeutics Quality Team per Section 6.2.2.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
42
Protocol No. 345-201-[ZIP_CODE]
43
Confidential - Proprietary Information Approval: [ADDRESS_1184554] received adequate treatment (ie, minimum 
therapeutic dose or higher) with a permitted ADT in the current epi[INVESTIGATOR_205470] 
[ADDRESS_1184555] 4 weeks prior to baseline (Day 1). Subjects who 
are taking ADTs other than the permitted ADTs will not be eligible for the trial.
Subjects who are eligible for randomization will be randomized into the trial and will 
receive either CT-[ADDRESS_1184556] be withdrawn. Additionally, treatment with more than one ADT 
during the trial, or other pharmacological augmentation, is not permitted.
Subjects are expected to maintain the ADT formulation identified at trial entry 
(ie, generic or branded) throughout their participation in the trial. The supply for the ADT 
can be provided by [CONTACT_851946] a mail order pharmacy or the subject can continue to 
take ADT that was previously prescribed before trial entry. 
If the subject does not continue to take ADT from the supply that was previously 
prescribed before trial entry, the ADT will be prescribed by [CONTACT_458] [INVESTIGATOR_851917] a mail order pharmacy and delivered to the subjectâ€™s home. Details 
are provided in the Site Operations Manual.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
43
Protocol No. 345-201-[ZIP_CODE]
44
Confidential - Proprietary Information Approval: 03 Nov 2021Subjects should maintain the type of ADT (generic or branded) during the trial period as 
before trial entry, regardless of the source of ADT supply.
6.[ADDRESS_1184557] after it is 
released for distribution.
Examples include, but are not limited to, communications involving failure/malfunction 
of a medicinal product or medical device to meet any of its specifications.
An investigational product nonconformance is the nonfulfillment of a specified product 
requirement during a clinical trial.
For this trial, all PQCs related to the digital mobile application (CT-152 or sham) are 
reportable. Any PQCs reported that are associated with the ADTs should be reported by [CONTACT_851947], pharmacist, and/or site investigator as appropriate.
[IP_ADDRESS] Eliciting and Reporting Product Quality Complaints and 
Product Nonconformance
During the trial, possible or suspected digital mobile application PQCs will be gathered 
by [CONTACT_851948] [IP_ADDRESS] . &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
45
Confidential - Proprietary Information Approval: [ADDRESS_1184558], trial site personnel, or sponsor, all calls and issues will 
be tracked. Simple technical issues will be resolved and marked as such. Issues 
determined to be possible or suspected PQCs will be transferred immediately to the Click 
Therapeutics Quality Team, which will follow its quality management system (QMS) 
processes for determining, investigating, and resolving PQCs. The Click QMS includes 
careful review of all reported issues, including those identified as product 
nonconformances, and incorporation of same into the product design records. 
Traceability between the call center system and the Click QMS will be maintained.
The investigator or designee must report all possible or suspected PQCs identified from 
the subject from the time of download of the digital mobile application, through the end 
of the subjectâ€™s trial participation. The investigator or designee must notify the call center 
within [ADDRESS_1184559] 
information and processes are detailed in the Site Operations Manual.
[IP_ADDRESS] Information Required for Reporting Purposes
ï‚·Description of complaint or nonconformance
ï‚·Reporter identification (eg, subject, investigator, site, etc.)
ï‚·Reporter contact [CONTACT_3031] (eg, phone number, e-mail address)
ï‚·Identification of material (product/compound name)
ï‚·Clinical protocol reference (number and/or trial name)
[IP_ADDRESS] Return Process
The digital mobile application will be uninstalled as described in Section 6.2.1.
[IP_ADDRESS] Assessment/Evaluation
Assessment and evaluation of digital mobile application malfunctions will be handled by 
[CONTACT_456], with support from the Click Therapeutics Quality Team.
6.3 Measures to Minimize/Avoid Bias
Procedures for breaking the blind can be found in Section 8.3.3.
Subjects part
icipating in this trial will be blinded to the efficacy hypothesis of the trial. 
Both treatment arms will be presented to the subject as possibly effective in treating 
symptoms of MDD. No references to CT-[ADDRESS_1184560] believes that both arms are possibly 
effective, they are less likely to question the efficacy of the treatment in which they were Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
45
Protocol No. 345-201-[ZIP_CODE]
46
Confidential - Proprietary Information Approval: [ADDRESS_1184561] facing documentation (ICF, informational brochures, etc.) 
neither CT-152, nor the sham will be named. Instead, reference will only be made to 
â€œdigital therapeuticâ€. This approach is limited to interventions that propose minimal risks, 
where withholding information will not adversely affect the subjectsâ€™ rights and welfare, 
and where the trial cannot practicably be carried out without withholding the information 
from the subject.
Potential investigator or trial site staff unblinding to the trial arms, which may occur 
during discussions between the subject and trial site staff, would not impact the MADRS 
assessments (primary efficacy endpoint as well as included in the other/additional 
efficacy endpoints) which will be collected by [CONTACT_851949]. This rater is managed by a 
centralized vendor external to the trial site. In order to protect blinding, the investigator 
and trial site staff will be trained not to provide any information to the independent rater, 
the subject, or the sponsor regarding the trial arms. The sponsorâ€™s trial management team 
will not have access to unblinded data codes and safeguards will be implemented to 
ensure that sponsor cannot access blinding codes during the trial.
A blinded and independent expert clinical rater, who will otherwise not interact with the 
subject, will rate and record the MADRS as described in Section 4.1. The inde pendent 
rater and subjects will be trained to avoid discussion of the content of the digital mobile 
application the subject receives or any other aspect of the trial participation. Any 
potential unblinding at the independent rater level may trigger replacement of the rater. 
All instances of unblinding of the independent rater during the trial will be recorded.
To further minimize potential bias, trial sites will designate at least [ADDRESS_1184562]-152 and 
sham groups, thus, there is no anticipated difference between groups in assessing 
adherence and the frequency of unblinding that could bias results in either direction.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
46
Protocol No. 345-201-[ZIP_CODE]
47
Confidential - Proprietary Information Approval: [ADDRESS_1184563] of 2 components: an 
EFMT exercise and a psychotherapy lesson. Each EFMT exercise consists of [ADDRESS_1184564] to encourage them to 
remain engaged during the treatment period.
Subjects who miss an individual digital mobile application session during the treatment 
period will receive automated adherence reminder messages on their mobile device. 
These may be delivered via push notification or text message.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
48
Confidential - Proprietary Information Approval: [ADDRESS_1184565] has been adherent to completing the 
sessions on the digital mobile application during the treatment period as required per the 
protocol. Adherence checks will be performed during the treatment period only. The 
schedule of assessments ( Table 1.3-1) includes adhere nce checks during the Week 1, 3, 
and 5 telephone contacts by [CONTACT_851950] 2 and 4 remote visits. There is no 
treatment schedule and no adherence requirements for the extension period.
The adherence checks are intended to identify subjects at risk of becoming â€˜nonadherentâ€™ 
and provide the investigator an opportunity to intervene as early as possible to maximize 
adherence across the trial.
Weekly adherence data will be obtained by [CONTACT_851951]â€™s mobile device. The code 
is calculated by [CONTACT_851952] 6.4.1. The code  will indicate to the investigator whether the subject has been 
adherent in the near term prior to the visit. Investigators will use this information to 
remind the subject to complete 3 sessions a week during the treatment period and to 
identify any technical issues that might be interfering with adherence. The language to be 
used by [CONTACT_851953].
6.5 Prior and Concomitant Medications or Therapi[INVESTIGATOR_851918] (pharmacological or other therapy) taken 
during the trial will be recorded in eSource.
The start date and stop date, if applicable, for all concomitant medication and 
nonpsychiatric treatments and therapi[INVESTIGATOR_851919] [ADDRESS_1184566] will be recorded in eSource.
The use of ADT will be confirmed at screening and throughout the trial and will be 
recorded in eSource.
6.5.1 Prohibited Medications or Therapi[INVESTIGATOR_851920] 6.5.2, the foll owing treatments are prohibited 
during the noted time frames and throughout trial participation. Subjects requiring a 
prohibited medication to control a medical condition should not be enrolled. Investigators Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
48
Protocol No. 345-201-[ZIP_CODE]
49
Confidential - Proprietary Information Approval: [ADDRESS_1184567] from the trial. The medical 
monitor should be contact[CONTACT_851954].
Within 90 Days Prior to Screening:
ï‚·Psychotherapy
Within 7 Days Prior to Randomization:
ï‚·Use of sedative hypnotics (except as defined in Section 6.5.2)
ï‚·Other psychotropic drugs or substances, eg, propranolol and mood stabilizers, even if 
they are being used for nonpsychiatric indications. Beta blockers for nonpsychiatric 
indications, except for propranolol, are permitted as described in Section 6.5.2.
ï‚·Other nonpsychopharmacologic drugs, substances, or herbal preparations with 
psychotropic effects
Within 14 Days Prior to Randomization:
ï‚·Anxiolytics (benzodiazepi[INVESTIGATOR_851921]). If subjects are taking 
anxiolytics at Day âˆ’14, the dose should be tapered and stopped prior to Day âˆ’1 
according to appropriate taper for benzodiazepi[INVESTIGATOR_851922].
Within 90 Days Prior to Randomization:
ï‚·Medications used to treat depression other than the ADT that is being utilized for the 
trial
Within 180 Days Prior to Randomization:
ï‚·Investigational drugs/procedures
At Any Time in the Past:
ï‚·ECT
ï‚·Neuro-modulation devices (transcranial magnetic stimulation, vagus nerve 
stimulation, or transcranial direct current stimulation, etc)
Use of a computer, web, or smartphone software-based application or equivalent for 
mental health or depression is prohibited during the trial.
Use of cannabis products is prohibited during the trial. Subjects reporting cannabis use or 
testing positive for cannabis may continue in the trial following medical monitor 
discussion and approval; however, subjects should be instructed not to use any cannabis Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
49
Protocol No. 345-201-[ZIP_CODE]
50
Confidential - Proprietary Information Approval: [ADDRESS_1184568] the potential efficacy of the digital 
intervention.
All treatments prohibited before screening or randomization are also prohibited during 
the trial.
6.5.2 Permitted Medications
One of the following will be required as background ADT (generic or branded is 
allowed):
Selective Serotonin Reuptake Inhibitors:
ï‚·Escitalopram (LexaproÂ®) tablets, 10 to 20 mg/day
ï‚·Citalopram (CelexaÂ®) tablets, 20 to 40 mg/day
ï‚·Fluoxetine (ProzacÂ®) capsules, 20 to 80 mg/day
ï‚·Paroxetine (Paxil CRÂ®) controlled-release tablets, 25 to 62.5 mg/day
ï‚·Paroxetine (PaxilÂ®) tablets, 20 to 50 mg/day
ï‚·Sertraline (ZoloftÂ®) tablets, 50 to 200 mg/day
Serotonin-norepi[INVESTIGATOR_75618]:
ï‚·Duloxetine (CymbaltaÂ®) delayed-release capsules, 60 to 120 mg/day
ï‚·Venlafaxine XR (Effexor XRÂ®) extended-release capsules, 150 to 225 mg/day
ï‚·Venlafaxine ER extended-release tablets, 150 to 225 mg/day
ï‚·Desvenlafaxine (PristiqÂ®) extended-release tablets, 50 to 100 mg/day
Other:
ï‚·Bupropi[INVESTIGATOR_188271] (WellbutrinÂ®) extended-release tablets or Bupropi[INVESTIGATOR_2394] (Wellbutrin) 
tablets, 300 mg/day
ï‚·Bupropi[INVESTIGATOR_60098] (Wellbutrin) sustained-release tablets, 300 to 400 mg/day
The following are other permitted concomitant treatments for this trial:
ï‚·As-needed use of common cold preparations. Subjects should be instructed not to 
take cold preparations within 24 hours before a remote visit.
ï‚·Use of the sedative hypnotics zolpi[INVESTIGATOR_6730], zaleplon, or eszopi[INVESTIGATOR_851923]. The 
maximum dose should not exceed 10 mg/night for these medications (zolpi[INVESTIGATOR_638283]-release: 12.5 mg/night), and use must not exceed 2 times per week. Subjects 
will be instructed not to take zolpi[INVESTIGATOR_6730], zaleplon, or eszopi[INVESTIGATOR_851924] 24 hours 
before a remote visit or 8 hours prior to using the digital mobile application.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
50
Protocol No. 345-201-[ZIP_CODE]
51
Confidential - Proprietary Information Approval: 03 Nov 2021ï‚·Use of nonbenzodiazepi[INVESTIGATOR_851925], but should not be used 8 hours 
prior to using the digital mobile application.
ï‚·Trazadone may also be used for the management of sleep in doses up to 100 mg per 
night, but should not be used 8 hours prior to using the digital mobile application.
ï‚·Use of beta blockers for nonpsychiatric indications (eg, hypertension) are permitted 
following consultation and approval by [CONTACT_7195]. Subjects must be on a 
stable dose for a minimum of 30 days prior to baseline (Day 1), without any changes 
in dosing expected for the trial duration. Note: the use of propranolol, regardless of 
indication, is prohibited during trial participation and must be discontinued 7 days 
prior to randomization as described in Section 6.5.1.
ï‚·Other medi
cations/treatments if not listed as prohibited in Section 6.5.1.
6.5.[ADDRESS_1184569]â€™s best medical interests should guide the investigator in the management of 
conditions that are pre-existing or that develop during the trial (intercurrent illness or 
AEs). For the AEs other than worsening of depressive symptoms, the investigator may 
initiate appropriate medications. If the subjects experience worsening of depression to 
such an extent that, in the investigatorâ€™s opi[INVESTIGATOR_1649], the subject cannot continue in the trial, 
the subject will be discontinued and treated with appropriate medications as per the 
standard of care.
6.6 Intervention After the End of the Trial
Not applicable.
7 Stoppi[INVESTIGATOR_1869], Withdrawal Criteria, and Procedures
7.1 Entire Trial or Treatment
If the sponsor terminates or suspends the trial for any reason, prompt notification will be 
given to investigators, institutional review boards (IRBs) and regulatory authorities in 
accordance with regulatory requirements.
7.2 Individual Site
Individual trial site participation may be discontinued by [CONTACT_456], the investigator, or 
the IRB if judged to be necessary for medical, safety, regulatory, ethical or other reasons 
consistent with applicable laws, regulations, and Good Clinical Practice (GCP). The 
investigator will notify the sponsor promptly if the trial is terminated by [CONTACT_851955].Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
51
Protocol No. 345-201-[ZIP_CODE]
52
Confidential - Proprietary Information Approval: [ADDRESS_1184570] may remain in the trial, even if nonadherent with the treatment sessions during 
the treatment period; all trial procedures should still be performed, including the primary 
and secondary endpoints and documentation of AEs and pharmacologic or other 
treatments that may have occurred.
7.3.[ADDRESS_1184571] discontinues or is withdrawn from the trial, the investigator will perform 
a final assessment, including the procedures indicated in the schedule of assessments 
(Table 1.3-1) for D a y [ADDRESS_1184572] debriefing (subjects who discontinue early 
before Week 6) or Day 70 (subjects who discontinue early from the trial after Week 6). 
The Day [ADDRESS_1184573] and rescheduling missed remote visits and 
telephone contacts within the Â± [ADDRESS_1184574]'s smartphone device will be 
uninstalled as described in Section 6.2.1.
7.3.[ADDRESS_1184575]-152 or sham for the reasons listed 
below:
ï‚·Adverse eventClinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
52
Protocol No. 345-201-[ZIP_CODE]
53
Confidential - Proprietary Information Approval: 03 Nov 2021ï€­Subject decides to discontinue because of annoyance or discomfort due to a 
nonserious AE which is not otherwise determined to be an undue hazard
ï€­Continuing CT-[ADDRESS_1184576] at undue risk as determined by [CONTACT_1275] (eg, a safety concern that is possibly, probably, or likely related to 
CT-152 or sham)
ï‚·Serious AE (SAE)
ï‚·Other safety concerns or AEs
ï‚·Death
ï‚·Failure to meet randomization criteria
ï‚·Lack of efficacy
ï‚·Lost to follow-up
ï‚·Physician decision
ï‚·Protocol deviation
ï‚·Trial site terminated by [CONTACT_3211]
ï‚·Required treatment with prohibited medication or therapy
ï‚·Trial terminated by [CONTACT_3211]
ï‚·Technical problems
ï‚·Withdrawal by [CONTACT_851956]-[ADDRESS_1184577]â€™s participation in the trial at any time if medically necessary. Unless 
the subject provides their written withdrawal of consent or there is other written 
documentation by [CONTACT_444470]â€™s verbal intent to completely 
withdraw from the trial, subjects should be followed for all protocol-specified evaluations 
and assessments, if possible.
Complete withdrawal of consent requires a subjectâ€™s refusal of ALL of the following 
methods of follow-up:
ï‚·Participation in all follow-up procedures specified in the protocol (whether remote 
visit or telephone contact).
ï‚·Participation in a subset of protocol-specified follow-up procedures (by a frequency 
schedule and method, as agreed by [CONTACT_330210]).Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
53
Protocol No. 345-201-[ZIP_CODE]
54
Confidential - Proprietary Information Approval: 03 Nov 2021ï‚·Contact [CONTACT_330211], even if only by [CONTACT_756], to assess current 
medical condition, and obtain necessary medical reports relevant to the trialâ€™s 
objectives.
ï‚·Contact [CONTACT_308705](s) who have been designated in source records as being 
available to discuss the subjectâ€™s medical condition, even if only by [CONTACT_756], mail, 
or e-mail (eg, family, spouse, partner, legal representative, friend, neighbor, or 
physician).
ï‚·Access to medical information from alternative sources (eg, hospi[INVESTIGATOR_307]/clinic medical 
records, referring doctorâ€™s notes, public records, dialysis, transplantation or vital 
registries, social media sources).
Withdrawal of consent is a critical trial event and, therefore, should be approached with 
the same degree of importance and care as is used in initially obtaining informed consent. 
The reasons for a subjectâ€™s intended withdrawal need to be completely understood, 
documented, and managed to protect the rights of the subject and the integrity of the trial. 
A subject may initially express their desire to interrupt or discontinue CT-152 or sham, 
which is not equivalent to a complete withdrawal of consent for further participation 
(see Section 7.3.1 and Section 7.3.2, respecti vely). A subject may, however, indicate that 
further trial participation is creating a burden on their work, school, or social schedule. 
Therefore, the investigator should follow the procedures outlined in Section 7.3.[ADDRESS_1184578] can continue participation in the trial if modifications to his/her 
treatment and/or schedule of assessments can be accommodated. Only subjects who 
withdraw their permission for all of the above methods of follow-up are considered to 
have completely withdrawn their consent to participate in the trial.
Subjects who were randomly assigned and withdraw from the trial will not be replaced, 
regardless of the reason for withdrawal.
If the subject withdraws from the trial, and also withdraws consent for disclosure of 
future information, no further evaluations should be performed, and no additional data 
should be collected. The sponsor may retain and continue to use any data collected before 
such withdrawal of consent.
7.[ADDRESS_1184579] to Follow-up
Subjects who cannot be contact[CONTACT_674545] 70 (Week 10), who do not have a 
known reason for discontinuation (eg, withdrew consent or AE), will be classified as 
â€œlost to follow-upâ€.
The trial site will make [ADDRESS_1184580] via certified mail or an alternative similar method, where appropriate, 
before assigning a â€œlost to follow-upâ€ status.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
54
Protocol No. 345-201-[ZIP_CODE]
55
Confidential - Proprietary Information Approval: [ADDRESS_1184581] was classified as â€œlost to follow-upâ€, â€œWere you able to contact [CONTACT_1560]?â€, â€œDate of contact/Date of final contact [CONTACT_103904]â€ and â€œContact [INVESTIGATOR_12183]â€ will be recorded in eSource.
8 Trial Procedures
Subjects will participate in the trial for up to 13 weeks. This includes a screening period of up to 3 weeks;  
 Extensions to the screening period, if 
requested by [CONTACT_093], may be granted after discussion and approval by [CONTACT_7195].
The treatment period will be for 6 weeks (Day 1 [baseline] to Week 6) and subjects will 
have a remote visit at Weeks 2, 4, and 6 and will be contact[CONTACT_30354] 1, 3 and 5. Subjects will be required to be adherent with their digital mobile application exercises during the treatment period.
After Week 6, subjects will continue participation in the trial during the extension period 
(Weeks 7 to 10). In the extension period, the digital mobile applications will remain installed for each group. Subjects will continue to receive brief SMS messages reminding subjects of the previously completed CT-152 or sham treatment courses (see Section 6.1.1  for further det ails), and will continue their ADT. Subjects will have a 
remote visit at Weeks [ADDRESS_1184582] a Â± [ADDRESS_1184583] on the designated trial day to ensure that the overall treatment period in the protocol has been maintained. Subsequent remote visits and telephone contacts should be based on the date of the baseline visit, not the previous remote visit/telephone contact. It is suggested that telephone contacts with the subject be scheduled in advance. If advanced scheduling is not possible, and the subject is not able to be reached by [CONTACT_851957], the trial site should make [ADDRESS_1184584] within the designated time frame.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
56
Confidential - Proprietary Information Approval: 03 Nov 2021The assessments to be conducted during the trial are summarized in the schedule of 
assessments ( Table 1.3-1 ). A brief summary of the assessments to be performed at each 
visit is provided below.
The screening procedures and data collection may be performed remotely or in person, at 
the discretion of the investigator, and a minimum of 7 consecutive days will be required for screening. The following information will be collected during the screening period:
â€¢Demographic information (collection date, age, sex, race, and ethnicity).
â€¢Medical history of significance including relevant surgical procedures. A general 
clinical evaluation will be performed, including concurrent medical conditions, medical history over the past 2 years, and medical history beyond 2 years that is considered to be clinically relevant per the investigatorâ€™s judgment.
â€¢Prior and concomitant medication including confirmation of ADT use per the 
eligibility criteria. The dose and schedule of ADT, start/stop dates, as well as whether brand or generic medication is being taken will be recorded.
â€¢Washout from prohibited concomitant medications, if applicable, will begin after 
consent has been obtained (see Section 6.5.1 ).
â€¢Psychiatric history and diagnosis, including description of all prior treatments for 
psychiatric disorders, start date of current epi[INVESTIGATOR_1865], and number of previous epi[INVESTIGATOR_1841]. This includes the DSM-[ADDRESS_1184585]â€™s diagnosis of MDD and to rule out exclusionary comorbid psychiatric disorders. Detailed instructions for administration of this structured interview will be provided.
â€¢The Antidepressant Treatment Response Questionnaire (ATRQ), used to collect a 
subjectâ€™s history of pharmacologic treatment for their current epi[INVESTIGATOR_1865], will be administered as part of the collection of a subjectâ€™s psychiatric history and will be utilized to determine eligibility for entry into the trial.
â€¢Substance usage history, current alcohol intake including amount and frequency, 
smoking status including history, and history of recreational drug use.
â€¢The following will be administered by [CONTACT_310623]: HAM-D
17 and C-SSRS.
â€¢The following will be completed by [CONTACT_423]: PHQ-9 and 
â€¢The subjects will also perform a urine pregnancy test (females of childbearing 
potential) and a urine drugs-of-abuse test.
â€¢The subject will download the digital mobile application onto their smartphone 
device.
â€¢Prior/concomitant therapy and AEs will be recorded.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
57
Confidential - Proprietary Information Approval: [ADDRESS_1184586]â€™s eligibility by [CONTACT_941] . Subjects cannot be enrolled until trial site personnel have received the final  notification from the medical monitor or clinical scientist. The investigator is responsible for ensuring that subjects are eligible for enrollment into the trial and for assessing subject safety throughout the trial.
As a means of improving subject safety and data quality, verification of subject eligibility 
will be cross-checked against a centralized trial subject database to identify potential violations. Data relating to dual enrollment, washout period, prior screen fails, and dual screenings will be reported. Subjects will be asked to authorize that their unique subject IDs be entered into a registry with the intent of identifying subjects who may meet exclusion criteria for participation in another clinical trial.
The following will be performed at the remote baseline visit on Day 1:
â€¢Confirmation of eligibility (including administration of the HAM-D
17 by [CONTACT_851958]).
â€¢Check of ADT compliance.
â€¢Randomization to 1 of 2 digital mobile applications (CT-152 or sham).
â€¢The baseline MADRS must be completed prior to or on the day of the baseline visit, 
or prior to usage of the digital therapeutic treatment following randomization. The MADRS is conducted by [CONTACT_851959].
â€¢The following will be administered by [CONTACT_310623]: CGI-S and C-SSRS.
â€¢The following will be completed by [CONTACT_423]: GAD-7 and WHODAS 2.0.
â€¢Prior/concomitant therapy and AEs will be recorded.
Treatment Period
The following will be performed during the remote visits at Weeks 2, 4, and 6:
â€¢Check of ADT compliance.
â€¢Adherence check of the use of the digital mobile application (Weeks 2 and 4 only).
â€¢The MADRS will be conducted by [CONTACT_851960]. Except for the 
baseline MADRS (see above), the MADRS at other visits may occur separately from the remote trial site visit but must be performed within the window.
â€¢The following will be administered by [CONTACT_310623]: CGI-S and C-SSRS.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
CCI
CCI
Protocol No. 345-201-[ZIP_CODE]
58
Confidential - Proprietary Information Approval: 03 Nov 2021â€¢The following will be completed by [CONTACT_423]: GAD-7, WHODAS 2.0 (Week 6 
only), PHQ-9 (Weeks 4 and 6 only),  and  
â€¢The principal investigator [INVESTIGATOR_851926] 
â€¢Concomitant medications and AEs will be recorded.
During each telephone contact [CONTACT_851961] 1, 3 and 5, concomitant 
medications and AEs will be recorded and an adherence check of the use of the digital mobile application will be performed.
Extension Period
The following will be performed during the remote visits at Weeks 8 and 10:
â€¢Check of ADT compliance.
â€¢The MADRS will be conducted by [CONTACT_851960]. The MADRS at 
Weeks [ADDRESS_1184587] be performed within the window.
â€¢The C-SSRS will be administered by [CONTACT_444485].
â€¢The GAD-[ADDRESS_1184588].
â€¢Concomitant medications and AEs will be recorded.
During each telephone contact [CONTACT_851961] [ADDRESS_1184589]. Trial site staff will describe the components of each digital therapeutic and discuss the trial hypothesis, (ie, that one digital therapeutic was hypothesized to be more beneficial in improving depression symptoms based on a small study conducted previously). Trial site staff should explain that a trial (ie, the one in which they participated) was needed to further evaluate these initial findings. Subjects will be told the reason for the hypothesis blinding, ie, subjects would be less likely to question the efficacy of the treatment in which they were assigned. Adequate protective measures and resources will be available in the instance a subject is adversely affected by &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI CCI
CCI
Protocol No. 345-201-[ZIP_CODE]
59
Confidential - Proprietary Information Approval: [ADDRESS_1184590] been properly trained may administer the 
clinician-administered scales. Assessments for the M.I.N.I., HAM-D
17, C-SSRS, and 
CGI-S will be administered by [CONTACT_851962]. Training on the 
administration of these assessments will be conducted.
No ratings as part of trial assessments may be performed by a rater prior to approval by 
[CONTACT_851963]/certification. It is preferred that as often as 
possible, for each subject, the site-administered scales be performed by [CONTACT_851964].
The GAD-7, PHQ-9, WHODAS 2.0,  will be 
completed by [CONTACT_683820]. The subjects will be encouraged to complete the assessments prior to but within the window of the scheduled remote visit. All subject self-assessments should be reviewed and verified by [CONTACT_851965], or within the window of the remote visit.
Every effort should be made to ensure that the protocol required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be circumstances, outside of the control of the investigator that may make it unfeasible to 
perform the test. In these cases, the investigator will take all steps necessary to ensure the 
safety and well-being of the subject. When a protocol required test cannot be performed the investigator will document the reason for this and any corrective and preventive actions which he/she has taken to ensure that normal processes are adhered to as soon as 
possible. The trial team will be informed of these incidents in a timely fashion.
8.1 Efficacy Assessments
8.1.1 Montgomery-Asberg Depression Rating Scale
The MADRS will be administered by a blinded and independent rater at the time points 
described in the schedule of assessments ( Table 1.3-1 ). The baseline  MADRS must be 
completed prior to or on the day of the baseline visit, or prior to usage of the digital therapeutic treatment following randomization. The MADRS at other visits may occur separately from the remote trial site visit but must be performed within the window.
The MADRS raters are selected, assigned, and managed by a central vendor separate 
from the trial sites.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
60
Confidential - Proprietary Information Approval: [ADDRESS_1184591]â€™s level of depression and 
must be administered utilizing the Structured Interview Guide for the MADRS (SIGMA). 
The MADRS consists of [ADDRESS_1184592] electronically within the window of the 
remote visits described in the schedule of assessments (Table 1.3-1). It is recomme nded 
that the GAD-7 be completed prior to the remote visit.
The GAD-7 is designed to assess anxiety in subjects. The scale contains 7 items and each 
item is rated from 0 (not at all) to 3 (nearly every day). The score ranges from 0 to 21. A 
higher score on the GAD-7 represents greater anxiety symptomatology.
8.1.3 Clinical Global Impressions-Severity
The CGI-S will be administered by [CONTACT_851966] ( Table 1.3-1).
The CGI-S is a standardized, clinician-administered global rating scale that measures 
disease severity on a 7-point Likert scale. A higher score on the CGI-S represents a 
higher severity of disease.
8.1.[ADDRESS_1184593] electronically within the window of the 
visits at the time points described in the schedule of assessments (Table 1.3-1). It is 
recommended that the PHQ-[ADDRESS_1184594] electronically within the window 
of the remote visits at the time points described in the schedule of assessments 
(Table 1.3-1). It is recomme nded that the  WHODAS 2.[ADDRESS_1184595]â€™s function and 
disability across 6 domains of life: cognition (understanding and communicating), 
mobility (moving and getting around), self-care (hygiene, dressing, eating, staying alone), Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
60
Protocol No. 345-201-[ZIP_CODE]
61
Confidential - Proprietary Information Approval: 03 Nov 2021getting along (interacting with others), life activities (domestic responsibilities, leisure, 
work and school), and participation (community and society).
 
 
 
 
 
 
 
 
 
8.[ADDRESS_1184596] safety.  The medical monitor should be consulted prior to clinical 
laboratory testing.
8.2.2 Suicidality Monitoring
Suicidality monitoring will occur at the time points described in the schedule of 
assessments ( Table 1.3-1 ).
In the event of clinically important treatment emergent suicidal ideation or suicidal 
behavior, as per the investigatorâ€™s judgment, the subject may be withdrawn from the trial 
and may receive appropriate medical care, which may include increasing the dose of ADT or using other medications as per the standard of care treatment for depression and/or access to a suicide hotline. The investigator will follow-up until the subjectâ€™s condition has stabilized.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
62
Confidential - Proprietary Information Approval: 03 Nov 2021Clinically important suicidality may include but is not limited to:
ï‚·Suicidal behavior (with or without intent of suicide or serious self-harm).
ï‚·Acute suicidality to such a degree that precaution against suicide must be exercised.
ï‚·Response of â€œyesâ€ to C-SSRS ideation items 4 or 5 or any of the C-SSRS behavioral 
items.
ï‚·Score of â€œ4â€, â€œ5â€, or â€œ6â€ on the MADRS suicidal thoughts item.
[IP_ADDRESS] Columbia-Suicide Severity Rating Scale
The C-SSRS will be administered by [CONTACT_851966] ( Table 1.3-1).
The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. The 
â€œBaseline/Screeningâ€ Version will be used for the first administration (at the screening 
visit). This version will evaluate a lifetime assessment of suicidal ideations and 
behaviors, as well a past 12-month evaluation of suicidal ideations and a past 24-month 
evaluation of suicidal behaviors. Subsequent visits will utilize the â€œSince Last Visitâ€ 
Version.
8.3 Adverse Events
8.3.1 Definitions
Note: The below definitions of AE, SAE, device-related AE, and unanticipated adverse 
device effect (UADE) are based on ISO14155 and 21 CFR 812 (and related US Food and 
Drug Administration [FDA] medical device clinical trial guidance documents).
Adverse event: Any untoward medical occurrence, unintended disease or injury, or 
untoward clinical sign in subjects, whether or not related to the digital therapeutic. 
Including any newly occurring event or previous condition that increases in severity or 
frequency following enrollment in the trial.
Note: Adverse events would not include information recorded as medical history at 
screening for preplanned procedures for which the underlying condition was known and 
no worsening occurred.
Serious AE: An AE where the outcome is one of the following:
a) Led to death
b) Led to a serious deterioration in the health of the subject, that either resulted in
1) A life-threatening illness or injury, or
2) A permanent impairment of a body structure or a body function, or
3) In-patient hospi[INVESTIGATOR_1081], orClinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
62
Protocol No. 345-201-[ZIP_CODE]
63
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE]) A medical or surgical intervention to prevent permanent life-threatening illness or 
injury or permanent impairment to body structure or a body function.
c) Led to fetal distress, fetal death, or a congenital abnormality
d) Other medically significant events that, based upon appropriate medical judgment, 
may jeopardize the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed above; eg, worsening of depression or anxiety 
symptoms; disease progression; suicidality (ideation); develop or resume drug 
dependency or drug abuse.
Note:
ï‚·Hospi[INVESTIGATOR_444437]; whenever possible the reason 
for the hospi[INVESTIGATOR_92657].
ï‚·Hospi[INVESTIGATOR_92658] (ie, those 
required for reasons of convenience or other nonmedical need) are not considered 
SAEs.
ï‚·Prescheduled hospi[INVESTIGATOR_444438] a condition that has existed prior to the 
signing of the ICF should not be considered an SAE.
Device-related AE: Events directly attributable to the device itself.
Unanticipated adverse device effect: Any serious adverse effect on health or safety or any 
life-threatening problem or death caused by, or associated with, a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence 
in the investigational plan, or any other unanticipated serious problem associated with a 
device that relates to the rights, safety, or welfare of subjects.
Nonserious AEs: All AEs that do not meet the criteria for a â€œseriousâ€ AE.
Severity: Adverse events will be graded on a 3-point scale and reported as indicated in 
the eSource. The severity of an adverse experience is defined as follows:
1 = Mild: Discomfort noticed, but no disruption to daily activity.
2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity.
3 = Severe: Inability to work or perform normal daily activity.
Causality: Assessment of causal relationship of an AE to the use of CT-152 is defined as 
follows:
Related: There is a reasonable possibility of a temporal and causal 
relationship between CT-152 and the AE.
Not Related: There is no temporal or causal relationship between CT-152 and 
the AE.
Additional definitions (based on Otsuka internal procedures):Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
63
Protocol No. 345-201-[ZIP_CODE]
64
Confidential - Proprietary Information Approval: 03 Nov 2021Treatment-emergent AEs (TEAEs): TEAEs are defined as an AE that began after at least 
one occurrence of CT-152 or sham; or if the event was continuous from baseline and was 
worsening, serious, related, or resulted in death, discontinuation, or interruption of 
investigational product.
8.3.2 Eliciting and Reporting Adverse Events
The investigator will regularly assess subjects for the occurrence of AEs. To avoid bias in 
eliciting AEs, subjects should be asked the nonleading question: â€œHow have you felt 
since your last visit?â€ All AEs (serious and nonserious) reported by [CONTACT_444476]. Adverse event 
collection will begin after a subject signs the ICF through the last visit or contact.
Medical terminology should be used for AE reporting. Adverse events should be reported 
as a single unifying diagnosis whenever possible or, in the absence of a unifying 
diagnosis, as individual signs or symptoms. Exacerbation or disease progression should 
be reported as an AE only if there are unusual or severe clinical features that were not 
present, or experienced earlier, or not expected based on the course of the condition.
A reported AE that undergoes a change in severity, seriousness, or toxicity should be 
reported as a new AE on the source documents and on the eSource provided by [CONTACT_103].
Adverse event, start date, end date, seriousness, severity, relationship to trial treatment 
(causality), action taken with trial treatment and outcome will be recorded on the source 
documents and in eSource.
[IP_ADDRESS] Anticipated Adverse Events
Adverse events related to mobile device use may include dizziness, fatigue, or headache. 
No attributable AEs to CT-[ADDRESS_1184597] a diagnosis of MDD per DSM-5  criteria. Any 
worsening of the symptoms associated with MDD, as well as other relevant comorbidities 
for this population including anxiety disorder or new or relapse to substance use are 
anticipated AEs for this population.
Efficacy assessments and safety variables per Section 8.1 and Section 8.2 capture s 
measurement criteria for some of these anticipated AEs. Subjects are under the care of 
qualified HCPs during the trial, and will be assessed for all AEs (anticipated as noted 
here) and unanticipated.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
64
Protocol No. 345-201-[ZIP_CODE]
65
Confidential - Proprietary Information Approval: [ADDRESS_1184598]-152, the sponsor 
believes, that there is no additional risks to the subjects.
[IP_ADDRESS] Device Malfunction
For the purposes of this trial, it is expected that device malfunctions will be observed by 
[CONTACT_311868]. In both cases, these will be reported to the call center 
and processed as described in Section 6.2.[ADDRESS_1184599] nonconformances.
[IP_ADDRESS] Unanticipated Adverse Device Effects
An unanticipated device adverse effect includes any serious adverse effect on health or 
safety or any life-threatening problem or death caused by, or associated with, a device, if 
that effect, problem, or death was not previously identified in nature, severity, or degree 
of incidence. Any unanticipated device adverse effect must be reported by [CONTACT_3719] e-mail 
to the sponsor or designee using the contact [CONTACT_851967] (within 24 hours). 
The sponsor will review all malfunctions and determine if they are unanticipated adverse 
device effects, and report to regulatory or other bodies (as appropriate).
[IP_ADDRESS] Immediately Reportable Events
Immediately Reportable Event:
ï‚·Any SAE (Note: all SAEs whether anticipated or not must be reported to the sponsor 
or sponsorâ€™s designee as immediately reportable events [IREs])
ï‚·Pregnancies are also defined as IREs. If the subject becomes pregnant during the trial, 
the subject should be discontinued. Pregnancy will only be documented on the AE 
eSource if there is an abnormality or complication. This does not include pregnancy 
of the partner of the subject.
ï‚·Any UADE
The investigator must immediately report (within 24 hours), using an IRE form, after the 
investigator or site personnel become aware of any IRE (SAE, confirmed pregnancy, or 
UADE), by [CONTACT_3719] e-mail to the sponsor or designee using the contact [CONTACT_851968] (Please note that the IRE form is NOT the AE eSource.).
Subjects experiencing SAEs should be followed clinically until their health has returned 
to baseline status, or until all parameters have returned to normal or have otherwise been 
explained. It is expected that the investigator will provide or arrange appropriate Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
65
Protocol No. 345-201-[ZIP_CODE]
66
Confidential - Proprietary Information Approval: [ADDRESS_1184600]â€™s status to 
the sponsor.
8.3.[ADDRESS_1184601] the sponsor/clinical research organization 
(CRO) medical advisor to discuss their rationale for unblinding. However, to prevent 
delays to the investigator or medical personnel responding to a potentially emergent 
situation, unblinding of CT-152 or sham will not be dependent upon the investigator 
receiving approval from the sponsor/CRO medical advisor (ie, the investigator will be 
able to obtain the code break information independent of the sponsor/CRO medical 
advisor). The investigator must contact [CONTACT_456]/CRO medical advisor by [CONTACT_16062] 
e-mail with an explanation of the need for opening the treatment assignment code within 
[ADDRESS_1184602] be notified immediately (see the cover page of this protocol for contact 
[CONTACT_3031]). Documentation of breaking the blind should be recorded in the subjectâ€™s 
medical record with the date and time the blind was broken and the names of the 
personnel involved. Once the blind is broken for a subject, that subject may not reinitiate 
treatment with CT-152 or sham.
8.3.4 Follow-up of Adverse Events
[IP_ADDRESS] Follow-up of Nonserious Adverse Events
Nonserious AEs that are identified at any time during the trial must be recorded on the 
AE eSource with the current status (ongoing or resolved/recovered) noted. All nonserious 
events (that are not IREs) that are ongoing at the last scheduled contact [CONTACT_851969]. For any AE having been identified throughout the trial, during 
analysis, additional relevant medical history information may be requested by [CONTACT_331675] (including, but not limited to, information such as risk-
related behavior, family history and occupation).
[IP_ADDRESS] Follow-up of Immediately Reportable Events
This trial requires that subjects be actively monitored for IREs up to [ADDRESS_1184603] be recorded as such on the AE eSource and the IRE form. If updated 
information (eg, resolved status) on IRE status becomes available after a subjectâ€™s last 
scheduled contact (up to the last remote visit or telephone contact [CONTACT_851970]), this Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
66
Protocol No. 345-201-[ZIP_CODE]
67
Confidential - Proprietary Information Approval: [ADDRESS_1184604] be reported to the sponsor and recorded in the AE eSource and the IRE form, 
according to the appropriate reporting procedures described in Section [IP_ADDRESS] .
It is expected that the investigator will provide or arrange appropriate supportive care for 
the subject and will provide prompt updates on the subjectâ€™s status to the sponsor. The investigator will follow IREs until the events are:
â€¢resolved,
â€¢stabilized,
â€¢the subject is lost to follow-up, or
â€¢has died.
Resolution means that the subject has returned to the baseline state of health and 
stabilized means that the investigator does not expect any further improvement or worsening of the subjectâ€™s condition. The investigator will continue to report any significant follow-up information to the sponsor up to the point the event has resolved or stabilized, or the subject is lost to follow-up, or has died.
Refer to Section 10.3  for additi onal information regarding the follow-up period for 
subjects that become pregnant.
[IP_ADDRESS] Follow-up and Reporting of Immediately Reportable Events 
Occurring After Last Scheduled Contact
[CONTACT_851971]-152 or sham, should be reported to the sponsor according to the procedures outlined in Section [IP_ADDRESS] . This may i nclude IREs that are captured on follow-up telephone 
contact [CONTACT_851972]-up information to the sponsor until the events are resolved or stabilized, or the subject is lost to follow-up or has died.
8.4 Other Assessments
 
 &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
68
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE].4.3 Mini International Neuropsychiatric Interview
The M.I.N.I. (Version 7.0.2 for DSM-5 ) will be used as a tool for conducting a structured 
interview for eligibility assessment at the screening visit ( Table 1.3-1 ).
The M.I.N.I. is a widely used structured diagnostic interview instrument developed for 
DSM-[ADDRESS_1184605] the interview.
The results of the M.I.N.I. will be compared with the inclusion/exclusion criteria for 
evaluation of comorbid diagnoses.
8.4.[ADDRESS_1184606]â€™s history of pharmacological treatment 
for their current epi[INVESTIGATOR_1865]. It will be administered at screening as part of the collection of the subjectâ€™s psychiatric history and will be utilized to determine eligibility for entry into the trial.
8.4.5 Hamilton Rating Scale for Depression, 17-Item
The HAM-D
17 will be administered by [CONTACT_851966] ( Table 1.3-1 ) as part of the el igibility assessments.
The HAM-D 17 will be administered utilizing the Structured Interview Guide for the 
Hamilton Depression Rating Scale (SIGH-D). Detailed instructions for administration of 
this structured interview will be provided.
8.4.[ADDRESS_1184607]â€™s DSM-5  diagnosis of MDD, based on the clinical interview and 
medical/psychiatric history and confirmed by [CONTACT_941] M.I.N.I., should be documented in eSource.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
69
Confidential - Proprietary Information Approval: [ADDRESS_1184608] performance/acquisition may be able to be accommodated 
following discussion with medical monitor.
Subjects with a positive urine drug screen resulting from use of cannabis, or prescription 
or over-the-counter medications, or products that, in the investigatorâ€™s documented 
opi[INVESTIGATOR_1649], do not signal a clinical condition that would impact the safety of the subject or 
interpretation of the trial results may continue evaluation for the trial following 
consultation and approval by [CONTACT_7195]. However, subjects will be instructed 
not to use cannabis products during the trial as per Section 6.5.1, as it ma y impact the 
potential efficacy of the digital intervention.  The investigator may retest a subject if it is 
believed a positive urine drug screen is a false positive test, following discussion with the 
medical monitor.
See Section 10.[ADDRESS_1184609] in 2 days (> [ADDRESS_1184610]) and provide evidence of the repeat test result to the trial site staff. Details 
can be found in the Site Operations Manual.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
69
Protocol No. 345-201-[ZIP_CODE]
70
Confidential - Proprietary Information Approval: [ADDRESS_1184611] performance/acquisition may be able to be accommodated 
following discussion with the medical monitor.
A confirmed positive pregnancy test result after signing the informed consent and before 
the baseline visit on Day 1, will require exclusion of the subject. A positive pregnancy 
test after the baseline visit will require discontinuation of the subject from the trial.
See Section 10.[ADDRESS_1184612]-152+ADT 
and sham+ADT in the change from baseline in MADRS total score with 85% power at a 
2-sided Î± = 0.[ADDRESS_1184613] deviation of 9. The resulting sample 
size is 324 evaluable subjects in total (162 subjects in each arm). To compensate for 
subjects that fail to have evaluable assessments of MADRS total score in the full analysis 
set (FAS) sample (estimated at up to 10% of all subjects), a total of 360 subjects 
(180 subjects in each arm) will be randomized in this trial.
Due to the limitations of applying assumptions on the treatment effect size, and in order 
to ensure adequate power of the trial, an unblinded interim analysis will be conducted by 
a Data Monitoring Committee (DMC; see Section 9.5.1). The fina l sample size  could be 
increased to 540 subjects (270 subjects in each arm) as per recommendation of the DMC. 
Using the Oâ€™Brien-Fleming spending function49 a signific ance level of 0.003 (2-sided) is 
allocated to this interim analysis. The corresponding final significance level is 0.049 
(2-sided).
The trial will randomize eligible subjects 1:1 across approximately 50 trial sites. The 
sample size at any single trial site will be capped at approximately 15% of the total 
number of randomized subjects. Randomization will be stratified by [CONTACT_121562].
9.2 Datasets for Analysis
The following analysis datasets are defined for this trial:
ï‚·Enrolled sample â€“ all subjects enrolled in the trial.
ï‚·Randomized sample â€“ all subjects allocated based on the randomization process and 
recorded in the database. Subjects treated without being randomized will not be 
considered as randomized and therefore will not be included in any efficacy or safety 
population analyses.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
70
Protocol No. 345-201-[ZIP_CODE]
71
Confidential - Proprietary Information Approval: 03 Nov 2021â€¢Safety sample â€“ all randomized subjects who receive at least [ADDRESS_1184614]-152 or sham use. All safety assessments will be performed on the safety analysis set. If any subjects receive a treatment that differs from the assigned treatment, then the safety analyses will be conducted on the treatment actually received.
â€¢FAS sample â€“ all randomized subjects who receive at least [ADDRESS_1184615] 1 postbaseline assessment of MADRS total score. Subjects included in the FAS sample are defined as evaluable subjects.
â€¢Per-protocol (PP) analysis sample â€“ all subjects in the FAS Sample who were treated 
for [ADDRESS_1184616]-152 or sham treatment in this trial. The classification of protocol deviations will be established in a blinded review by [CONTACT_104222] a meeting prior to breaking the blind. The PP analysis set will only be used for sensitivity analysis of the primary efficacy and key secondary variables.
9.3 Handling of Missing Data for Primary and Secondary Endpoint 
Analysis
When the possibility of â€œmissing not at randomâ€ cannot be ruled out, a selection model, 
pattern-mixture model, and other models will be used to explore the impact of missing 
data and potential mechanisms of â€œmissing not at randomâ€ and investigate the response 
profile of dropout reasons. See Section [IP_ADDRESS]  for more det ails.
9.[ADDRESS_1184617]-152+ADT and sham+ADT, 
based on the primary efficacy endpoint, is that the change in MADRS using 
CT-152+ADT is equal to the change in MADRS using the sham+ADT.
H0: Î”Î¼ MADRS CT-152+ADT  = Î”Î¼ MADRS sham+ADT
HA: Î”Î¼ MADRS CT-152+ADT  â‰  Î”Î¼ MADRS sham+ADT
The primary analysis will be conducted on the change from baseline in MADRS total 
score to the final on-therapy evaluation (Week 6) based on the FAS Sample adjusted for the baseline MADRS total score.
 
   
 
 &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
72
Confidential - Proprietary Information Approval: 03 Nov 2021 
 
[IP_ADDRESS].[ADDRESS_1184618] in the protocol uses the 
hypothetical strategy specified in the International Council for Harmonisation (ICH) E9 Addendum. The objective of the primary analysis is to compare the efficacy of CT-[ADDRESS_1184619] collected efficacy assessment after premature trial discontinuation will be done only once at the early termination (ET) visit. Every effort will be made to complete all of the ET evaluations 
prior to administering any other treatment. In the case of terminal or lost to follow-up 
events no ET evaluations would be expected, and only scheduled assessments performed 
before such an event has occurred. 
The primary estimand for this trial is defined by [CONTACT_13673]:
â€¢Target population: FAS Sample
â€¢Endpoint: change from baseline to Week 6 in the MADRS total score
â€¢Intercurrent events: premature treatment discontinuation
â€¢Measure of intervention effect: difference in endpoint means between CT-152+ADT 
and sham+ADT
In this hypothetical strategy, the event of withdrawing CT-152+ADT or sham+ADT is 
considered missing at random (MAR), and the primary endpoint of the trial could be considered as a combination of the measurements of on-treatment completers at Week 6 and the imputation of the endpoint to Week 6 following the trend in each treatment group using the mixed model repeated measurements (MMRM) method to impute missing data for subjects who withdraw CT-152+ADT or sham+ADT during the trial. All data collected during the trial treatment period will be used for statistical analysis. For the 
primary efficacy analysis, the treatment effect will be estimated using the MMRM 
method described in Section [IP_ADDRESS].[ADDRESS_1184620] for the treatment period. Analyses with missing values imputed by [CONTACT_851973] (MNAR), and other methods will be performed as sensitivity analyses.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
73
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE].[IP_ADDRESS] Primary Analysis Method
The primary analysis will utilize a MMRM with treatment, visit, treatment by [CONTACT_150133], and site as fixed effects to assess heterogeneity of treatment effects. This 
model will also include an interaction term of visit by [CONTACT_851974] a 
covariate. Observed data from all planned visits during the 6-week treatment period will 
be included in the model. An unstructured covariance matrix will be used to model the 
within subject variance. The primary comparison between the CT-152+ADT or 
sham+ADT at Week [ADDRESS_1184621] squares means 
utilizing the computing software SAS procedure PROC MIXED.
The mathematical formula for the MMRM model is as follows:
ð’š=ð‘¿ð›½+ð‘ð‘¢+ðœ–
Where
 ð’š denotes the observed vector of change from baseline to Week 6 in MADRS total score;
 ð‘¿ is the known matrix for the fixed effects and covariate;
ð›½ is an unknown fixed-effect parameter vector; 
ð‘ is the known matrix for the random effect of subject;
ð‘¢ is an unknown vector of random effect of subject with mean 0 and variance-covariance 
matrix G (unstructured covariance matrix); 
ðœ– is an unknown vector of random errors with mean 0 and variance R.
In case there is a convergence problem with the MMRM model with the unstructured 
variance-covariance matrix, the following structures other than unstructured will be used 
in order of 1) heterogeneous toeplitz, 2) heterogeneous autoregressive of order 1, and 3) 
heterogeneous compound symmetry. The first (co)variance structure converging to the 
best fit will be used as the primary analysis. If a structured covariance has to be used, the 
â€œsandwichâ€ estimator of the standard error of the fixed effects parameters will be used in 
order to deal with possible model misspecification of the covariance matrix.
Small trial sites will be defined as trial sites that do not have at least one evaluable 
subject (evaluable with regard to the primary efficacy variable) in each treatment arm. All 
small trial sites will be pooled to form â€œpseudo sitesâ€ for the purpose of analysis 
according to the following algorithm. Small trial sites will be ordered from the largest to 
the smallest based on the number of evaluable subjects (ie, subjects who have baseline 
and at least one postbaseline value for the primary endpoint in the treatment period).Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
73
Protocol No. 345-201-[ZIP_CODE]
74
Confidential - Proprietary Information Approval: [ADDRESS_1184622] nonsmall trial site.
[IP_ADDRESS] Analyses on Key Secondary Efficacy Endpoint and 
Other/Additional Efficacy Endpoints
The key secondary efficacy endpoint and other/additional efficacy endpoints will be 
analyzed based on the FAS as described for the primary analysis.
To control the overall type I error, the statistical tests based on the primary efficacy 
endpoint and the key secondary efficacy endpoint will be done using a hierarchical 
approach. The primary hypothesis will be tested at the 0.049 level and if successful in 
rejecting the null hypothesis stated above, analysis of the key secondary endpoint will be 
tested at the type I error level of 0.049.
Should the primary outcome not achieve statistical significance, the key secondary 
endpoint will be examined as an other efficacy endpoint.
[IP_ADDRESS].1 Key Secondary Efficacy Endpoint Analysis
Change from baseline to Week 6 in the GAD-7 total score will be analyzed using the 
same method (MMRM) as in the primary analysis with a replacement of the interaction 
term of visit by [CONTACT_851937]-[ADDRESS_1184623]-152+ADT and sham+ADT, based on the key secondary 
efficacy endpoint, is that the change from baseline to Week [ADDRESS_1184624]-152+ADT is equal to the change from baseline to Week 6 in the GAD-7 total 
score using sham+ADT.
H0: Î”Î¼ GAD-7 CT-152+ADT  = Î”Î¼ GAD-7 sham+ADT
HA: Î”Î¼ GAD-7 CT-152+ADT  â‰  Î”Î¼ GAD-7 sham+ADT
where Î”Î¼ GAD-7 CT-152+ADT  and Î”Î¼ GAD-7 sham+ADT  are the change from baseline to 
Week [ADDRESS_1184625]-152+ADT and sham+ADT treatment groups, 
separately.
[IP_ADDRESS].[ADDRESS_1184626]-152 will be assessed based on MADRS total score and 
GAD-7 total score.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
74
Protocol No. 345-201-[ZIP_CODE]
75
Confidential - Proprietary Information Approval: [ADDRESS_1184627]-152 compared to 
sham. Such point estimates will be provided using the same MMRM model in the key 
secondary efficacy analysis with change from baseline in GAD total score at Week 8 and 
10 as the dependent variable.
[IP_ADDRESS].3 Other Efficacy Endpoints Analyses
Change from baseline to Weeks 2 and 4, separately, in the MADRS total score will be 
analyzed using the same MMRM model in the primary efficacy analysis. 
Change from baseline to Weeks 2 and 4, separately, in the GAD-7 total score will be 
analyzed using the same MMRM model in the key secondary efficacy analysis.
Response on the MADRS is defined as a decrease of 50% or more on the MADRS total 
score from baseline. Response rates at Weeks 2, 4, and 6, separately, will be analyzed 
using the Cochran-Mantel-Haenszel General Association Test controlling, in last 
observation carried forward (LOCF) analyses, for trial site.
H0: Ï€ CT-152+ADT  = Ï€ sham+ADT 
HA: Ï€ CT-152+ADT  â‰  Ï€ sham+ADT
Where Ï€ CT-152+ADT  and Ï€ sham are the proportion of MADRS response rates at Weeks 2, 4, 
and [ADDRESS_1184628]-152+ADT and sham+ADT treatment groups, separately.
Change from baseline to Weeks 2, 4, and 6, separately, in CGI-S score will be analyzed 
using the same method as in the primary analysis with a replacement of the interaction 
term of visit by [CONTACT_851975]-S score as a covariate. The hypothesis tested is the null 
hypothesis that the change from baseline to each schedule week (Weeks 2, 4, and 6) in 
the CGI-S score using CT-152+ADT is equal to the change from baseline to each 
schedule week (Weeks 2, 4, and 6) in the CGI-S score using the sham+ADT.
H0: Î”Î¼ CGI-S CT-152+ADT  = Î”Î¼ CGI-S sham+ADT
HA: Î”Î¼ CGI-S CT-152+ADT  â‰  Î”Î¼ CGI-S sham+ADTClinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
75
Protocol No. 345-201-[ZIP_CODE]
76
Confidential - Proprietary Information Approval: [ADDRESS_1184629]-152+ADT  and Î”Î¼ CGI-S sham+ADT are the changes from baseline to Weeks 
2, 4, and [ADDRESS_1184630]-152+ADT and sham+ADT treatment groups, separately.
Change from baseline to Week [ADDRESS_1184631]-152+ADT is 
equal to the change from baseline to Week 6 in the WHODAS 2.0 total score using the 
sham+ADT.
H0: Î”Î¼ WHODAS 2.0 CT-152+ADT  = Î”Î¼ WHODAS 2.0 sham+ADT
HA: Î”Î¼ WHODAS 2.0 CT-152+ADT  â‰  Î”Î¼ WHODAS 2.0 sham+ADT
Where Î”Î¼ WHODAS 2.0 CT-152+ADT  and Î”Î¼ WHODAS 2.0 sham+ADT are the changes from 
baseline in Week [ADDRESS_1184632]-152+ADT and sham+ADT 
treatment groups, separately.
Change from screening to Weeks 4 and 6, separately, on the PHQ-9 total score will be 
analyzed using the same method as in the primary analysis with a replacement of the 
interaction term of visit by [CONTACT_851976]-9 total score as a covariate. The hypothesis 
tested is the null hypothesis that the change from screening to each schedule week 
(Weeks 4 and 6) in the PHQ-[ADDRESS_1184633]-152+ADT is equal to the change 
from screening to each schedule week (Weeks 4 and 6) in the PHQ-9 total score using the 
sham+ADT.
H0: Î”Î¼ PHQ-9 CT-152+ADT  = Î”Î¼ PHQ-9 sham+ADT
HA: Î”Î¼ PHQ-9 CT-152+ADT  â‰  Î”Î¼ PHQ-9 sham+ADT
Where Î”Î¼  PHQ-9 CT-152+ADT  and Î”Î¼ PHQ-9 sham+ADT are the changes from screening to 
Weeks [ADDRESS_1184634]-152+ADT and sham+ADT treatment groups, 
separately.
Partial response on the MADRS is defined as â‰¥ 30% and < 50% reduction in MADRS 
total score from baseline. Partial response rates at Weeks 2, 4, and 6, separately, will be 
analyzed using the same statistical model for MADRS response.
H0: Ï€ CT-152+ADT  = Ï€ sham+ADT  
HA: Ï€ CT-152+ADT  â‰  Ï€ sham+ADTClinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
76
Protocol No. 345-201-[ZIP_CODE]
77
Confidential - Proprietary Information Approval: [ADDRESS_1184635]-152+ADT  and Ï€sham+ADT  are the MADRS partial response rates at Weeks 2, 4, 
and [ADDRESS_1184636]-152+ADT and sham+ADT treatment groups, separately.
Response on the MADRS during the extension period is defined as full or partial, defined 
as â‰¥ 30% reduction in MADRS total score from baseline. Response rates at Weeks 8 and 
10, separately, will be analyzed using summary statistics in LOCF analysis.
[IP_ADDRESS] Control of Experiment-wise Type 1 Error
To control experiment-wise type I error, a hierarchical approach on the primary and key 
secondary efficacy endpoints will be applied as described in Section [IP_ADDRESS] .
[IP_ADDRESS] Sensitivity Analyses
Per-protocol analyses will be conducted as sensitivity analyses to the primary analysis, on 
the PP analysis set.
The MMRM model used for the primary efficacy endpoint assumes data are MAR, which 
is a reasonable assumption in longitudinal clinical trials in MDD.52 However, the 
possibility of â€œmissing not at randomâ€ (MNAR) data can never be ruled out. As 
sensitivity analyses, selection model53 patte rn-mixture model54,55,56,57 and shared 
parameter model58 will al l be used to explore data missing mechanisms of MNAR and 
investigate the response profile of dropout reason. Adding a site by [CONTACT_851977].
Subgroup analysis will be performed on gender, race, age group, and by [CONTACT_851978] (Yes/No).  &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
Protocol No. 345-201-[ZIP_CODE]
78
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE].4.2 Safety Analysis
[IP_ADDRESS] Adverse Events
All AEs will be coded by [CONTACT_331682] (MedDRA) preferred term. The incidence of the following events will be summarized by [CONTACT_1570]:
â€¢TEAEs
â€¢TEAEs potentially causally related to CT-152 or sham
â€¢TEAEs with an outcome of death
â€¢Serious TEAEs
â€¢TEAEs leading to discontinuation from the trial
[IP_ADDRESS] Clinical Laboratory Data
Urine drugs-of-abuse screen and pregnancy test results will be listed by [CONTACT_1130].
[IP_ADDRESS] Other Safety Data
Rates of the incidence of worsening depressive symptoms during the treatment period 
(depressive symptom severity entering the â€œsevereâ€ range: CGI-S increase of 2 or more 
points from baseline, or as judged by [CONTACT_851979]) and the incidence of 
emergent clinically important suicidality (as described in Section 8.2.2 ) will be c ompared 
between CT-152 and sham groups in the safety analysis sets. Rates and their 95% 
confidence intervals will be reported and the estimated differences between groups will 
be provided.
9.4.3 Other Analyses
[IP_ADDRESS] Analysis of Demographic and Baseline Characteristics
Baseline and demographic characteristics including age, sex, race, and ethnicity will be 
summarized using descriptive statistics.
 
9.[ADDRESS_1184637] 180 randomized subjects. The unblinded interim analysis will be carried out when &OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
79
Confidential - Proprietary Information Approval: [ADDRESS_1184638] the overall type I error at the 2-sided alpha level of 0.05 (2-sided) and to limit the estimation bias, the following will be completed:
â€¢A significance level of 0.003 (2-sided) will be allocated to this unblinded interim 
analysis. The corresponding final significance level is 0.049 (2-sided).
â€¢The DMC will be allowed to make recommendations based on 1 of the 4 outcomes:
â€¢Early stop for efficacy if the unblinded interim analysis p-value is < 0.003 
(2-sided; Early Efficacy), and all point estimates of difference in change from baseline to Weeks 6, 8, and 10 in MADRS total score 
â€¢Proceed as planned to 360 randomized subjects if the conditional power observed 
at the unblinded interim analysis is â‰¥ 85%; or is > 15% and â‰¤ 50% (Favorable or 
Unfavorable Zone).
â€¢Increase sample size from 360 randomized subjects to 540 randomized subjects, if 
the conditional power observed at the unblinded interim analysis is > 50% but < 85% (Promising Zone).
â€¢Early stop for futility if the conditional power observed at the unblinded interim 
analysis is â‰¤ 15% (Futility).
The sample size will be re-estimated only based on the conditional power determined at 
the interim analysis. The adaptive designs methodology published by [CONTACT_92709], DeMets, and 
Lan (2004)
[ADDRESS_1184639] expertise in MDD treatment trials. The DMC will be convened at intervals described in the DMC charter to review data on recruitment, retention, interim analysis, and safety (including evaluation of discontinuation criteria), and to review data for completeness and quality during the trial. Discontinuation criteria will be prespecified and included in the DMC charter.&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
Protocol No. 345-201-[ZIP_CODE]
80
Confidential - Proprietary Information Approval: 03 Nov 202110 Supporting Documentation and Operational Considerations
10.1 Appendix 1: Regulatory, Ethical, and Trial Oversight 
Considerations
10.1.[ADDRESS_1184640] be conducted in compliance with the protocol, FDA regulations ICH GCP 
guidance international ethical principles derived from the Declaration of Helsinki and 
Council for International Organizations of Medical Science (CIOMS) guidelines, and 
applicable local laws and regulations. Each trial site will seek approval/favorable opi[INVESTIGATOR_674522], and the investigator will provide that 
documentation to the sponsor. The IRB will evaluate the ethical, scientific and medical 
appropriateness of the trial. Further, when working with eSource, the investigator, 
subinvestigator and their staff will take measures to ensure adequate care in protecting 
subject privacy. To this end, a subject ID will be used to identify each subject.
Financial aspects, subject insurance and the publication policy for the trial will be 
documented in the agreement between the sponsor and the investigator.
10.1.2 Informed Consent
If the screening visit is performed in person, the informed consent process will be 
performed at the trial site.
If the screening visit is performed remotely, the informed consent process will be 
performed remotely.
Informed consent will be freely obtained from all subjects (or their guardian or legally 
acceptable representative, as applicable for local laws). The ICF will be approved by [CONTACT_331683].
Each ICF will comply with the ICH GCP: Consolidated Guideline E6 and local 
regulatory requirements. The investigator will ensure that the sponsor reviews and 
authorizes any written site-specific ICF used in the trial before submission to the IRB. 
This trial will utilize an electronic informed consent form (eICF). The eICF utilizes the 
IRB-approved trial site-specific ICF to offer subjects an enhanced platform to review and 
understand their rights as a trial subject as well as required trial procedures. Trial sites 
will have subjects review and sign the eICF prior to starting any trial procedures.
Investigators may discuss trial availability and the possibility for entry with a potential 
subject without first obtaining consent. However, informed consent must be obtained and Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
80
Protocol No. 345-201-[ZIP_CODE]
81
Confidential - Proprietary Information Approval: 03 Nov 2021documented before initiation of any procedures that are performed solely for the purpose 
of determining eligibility for this trial, including withdrawal from current medication(s). 
Potential subjects are free to refuse entry into the trial, or withdraw from the trial at any 
time, without justification, and there will be no consequences to their further care.
Prospective trial subjects will be provided with controlled access to the eICF application 
by [CONTACT_444485]. When the trial site staff and the subject agree that the subject has 
enough information to make an informed decision to participate, the subject will 
electronically sign in the eICF application and an electronic date and timestamp will be 
applied to the signature. The subject will be provided a signed copy of the ICF. Any other 
parties required by [CONTACT_1201] (trial site staff, witnesses, or legally authorized 
representative) are also required to sign electronically and these signatures will be stored 
with the eICF in accordance with the ICH GCP Guideline and local regulatory 
requirements/guidelines. These signatures cannot be altered, removed, or copi[INVESTIGATOR_530].
Subjects may be asked to sign additional ICFs if the protocol is amended and the changes 
to the protocol results in additional information that needs to be provided to the subjects, 
so that they can make a knowledgeable and voluntary decision on continued trial 
participation.
All subjects who have consented to participate in the trial will be given the opportunity to 
provide consent for tokenization. Participation in the tokenization is optional and a 
separate and similar consent process will be followed for the tokenization. Tokenization 
is further described in Section 10.4.
10.1.3 Confidentiality
All information generated in this trial will be considered confidential and will not be 
disclosed to anyone not directly concerned with the trial without the sponsorâ€™s prior 
written permission. Subject confidentiality requirements of the region(s) where the trial is 
conducted will be met. However, authorized regulatory officials and sponsor personnel 
(or their representatives) may be allowed full access to inspect and copy the records, 
consistent with local requirements. CT-152, sham, and/or other materials collected shall 
be used solely in accordance with this protocol, unless otherwise agreed to in writing by 
[CONTACT_456].
Subjects will be identified only by [CONTACT_572615]. If further subject 
identification is required, subjectsâ€™ full names may be made known to a regulatory 
agency or other authorized officials if necessary, subject to local regulations.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
81
Protocol No. 345-201-[ZIP_CODE]
82
Confidential - Proprietary Information Approval: 03 Nov 202110.1.4 Quality Control and Quality Assurance
[IP_ADDRESS] Monitoring
The sponsor has ethical, legal, and scientific obligations to follow this trial in accordance 
with established research principles, the ICH GCP: Consolidated Guideline (E6), and 
applicable regulatory requirements and local laws. As part of a concerted effort to fulfill 
these obligations (maintain current personal knowledge of the progress of the trial), the 
sponsorâ€™s monitors will visit or conduct video conferencing with the trial sites during the 
trial, as well as communicate frequently via telephone, e-mail, and written 
communications. In addition, all investigators and trial site personnel will undergo initial 
and ongoing training for this particular trial, and this training will be clearly documented.
[IP_ADDRESS] Auditing
The sponsor's Quality Assurance Unit (or representative) may conduct trial site audits. 
Audits will include, but are not limited to, presence of required documents, the informed 
consent process, and a review of the eSource with source documents, as applicable. The 
investigator agrees to participate with audits.
Regulatory authorities may inspect the trial sites during or after the trial. The 
investigators will cooperate with such inspections and will contact [CONTACT_331687].
10.1.5 Protocol Deviations
In the event of a significant deviation from the protocol due to an emergency, accident, or 
mistake (eg, violation of informed consent process, treatment assignment error, subject 
enrolled in violation of eligibility criteria or concomitant medication criteria), the 
investigator or designee will contact [CONTACT_851980] e-mail. The investigator and sponsor (or designee) will come as 
quickly as possible to a joint decision regarding the subjectâ€™s continuation in the trial. 
This decision will be documented by [CONTACT_31376] (or designee) and 
reviewed by [CONTACT_25007].
Any major protocol deviation will be recorded in eSource along with the start date and 
details of the deviation.
10.1.6 Records Management
[IP_ADDRESS] Source Documents
Source documents are defined as the results of original observations and activities of a 
clinical investigation. Source documents will include but are not limited to medical Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
82
Protocol No. 345-201-[ZIP_CODE]
83
Confidential - Proprietary Information Approval: [ADDRESS_1184641] inspection by [CONTACT_92718].
Investigator(s)/institution(s) will permit trial-related monitoring, audits, IRB review, and 
regulatory inspection(s) by [CONTACT_20618]/documents by 
[CONTACT_331690]. In all cases, subject confidentiality must be 
maintained in accordance with local regulatory requirements.
[IP_ADDRESS] Data Collection
Source documents and source data will be captured electronically (where permitted by 
[CONTACT_1295]) in this trial and will meet the same fundamental elements of data quality 
(eg, attributable, legible, contemporaneous, original, and accurate) as paper records. 
These data will be collected into a system that is fully validated according to [ADDRESS_1184642] directly populates the 
trial database.
Some data may be captured via paper and then entered into the eSource system. These 
and any other data treated in this manner will be source data verified per the monitoring 
plan and the location of the source data (ie, eSource, paper, or a local electronic system) 
will be documented before the trial start. Any changes to information in paper source 
documents will be initialed and dated on the day the change is made by a trial site staff 
member authorized to make the change. Changes will be made by [CONTACT_2724] a single line 
through erroneous data (so as not to obliterate the original data), and clearly entering the 
correct data (eg, wrong data right data). If the reason for the change is not apparent, a 
brief explanation for the change will be written in the source documentation by [CONTACT_451438].
Remote monitoring of the original electronic source records will take place; however, 
on-site monitoring inspections will continue to take place in order to review data entry of 
source documentation directly captured on paper and transcribed into the system, to Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
83
Protocol No. 345-201-[ZIP_CODE]
84
Confidential - Proprietary Information Approval: [ADDRESS_1184643] data.
[IP_ADDRESS] File Management at the Trial Site
The investigator will ensure that the trial site file is maintained in accordance with 
Section 8 of t he ICH GCP: Consolidated Guideline (E6) and as required by [CONTACT_713530]. The investigator/institution will take measures to prevent accidental or 
premature destruction of these documents.
[IP_ADDRESS] Records Retention at the Trial Site
Food and Drug Administration regulations require all investigators participating in 
clinical drug trials to maintain detailed clinical data for one of the following periods:
ï‚·A period of at least 2 years after the date on which a New Drug Application is 
approved by [CONTACT_1622];
ï‚·A period of [ADDRESS_1184644] not dispose of any records relevant to this trial without either 
(1) written permission from the sponsor or (2) provision of an opportunity for sponsor to 
collect such records. The investigator will be responsible to maintain adequate and 
accurate electronic or hard copy source documents of all observations and data generated 
during this trial including any data clarification forms received from the sponsor. Such 
documentation is subject to inspection by [CONTACT_331692]. 
If the investigator withdraws from the trial (eg, due to relocation or retirement), all 
trial-related records should be transferred to a mutually agreed-upon designee within a 
sponsor-specified time frame. Notice of such transfer will be given to the sponsor in 
writing.
[IP_ADDRESS] Publication Authorship Requirements
Authorship for any Otsuka-sponsored publications resulting from the conduct of this trial 
will be based on International Committee of Medical Journal Editors (ICMJE) authorship 
criteria (http://www.icmje.org/recommendations). According to ICMJE guidelines, one 
may be considered an author only if all of the following criteria are met:
1) Substantial contributions to the conception or design of the work; or the 
acquisition, analysis, or interpretation of data for the work; ANDClinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
84
Protocol No. 345-201-[ZIP_CODE]
85
Confidential - Proprietary Information Approval: 03 Nov [ZIP_CODE]) Drafting the work or revising it critically for important intellectual content; AND
3) Final approval of the version to be published; AND
4) Agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved.
All authors must meet the above criteria, and all who qualify for authorship based on the 
above criteria should be listed as authors.
Investigators or other trial subjects who do not qualify for authorship may be 
acknowledged in publications resulting from the trial. By [CONTACT_92726], investigators or other trial subjects consent to such acknowledgement in any 
publications resulting from its conduct.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
85
Protocol No. 345-201-[ZIP_CODE]
86
Confidential - Proprietary Information Approval: 03 Nov 202110.2 Appendix 2: Urine Drugs-of-Abuse Screen
The urine drugs-of-abuse screen will test for the following:
ï‚·Methamphetamines
ï‚·Cocaine
ï‚·Benzodiazepi[INVESTIGATOR_1651]
ï‚·Oxycodone
ï‚·Morphine
ï‚·Tetrahydrocannabinol
ï‚·Phencyclidine
ï‚·Adulteration detection for oxidants, creatinine, pH, specific gravity, nitrites, and 
glutaraldehydeClinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
86
Protocol No. 345-201-[ZIP_CODE]
87
Confidential - Proprietary Information Approval: 03 Nov 202110.3 Appendix 3: Contraceptive Guidance and Collection of Pregnancy 
Information
There is no contraceptive guidance for this trial.
The investigator must immediately notify the sponsor (within 24 hours) of any pregnancy 
during the trial and for up to [ADDRESS_1184645] 
the Pregnancy Surveillance Form(s) to the investigator for monitoring the outcome of the 
pregnancy.
Protocol required procedures and follow-up must be performed on the subject unless 
contraindicated by [CONTACT_8663] (eg, x-ray studies). Other appropriate pregnancy follow-up 
procedures should be considered if indicated. In addition, the investigator must report to 
the sponsor, on the Pregnancy Surveillance Form(s), follow-up information regarding the 
course of the pregnancy, including perinatal and neonatal outcome. Infants will be 
followed for a minimum of 6 months from the date of birth.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
87
Protocol No. 345-201-[ZIP_CODE]
88
Confidential - Proprietary Information Approval: 03 Nov 202110.4 Appendix 4: Tokenization
Linking subject data collected during a clinical trial to subject data collected outside of 
the trial (eg, real-world data [RWD] such as health insurance claims, electronic medical 
records, laboratory data from outside the trial, etc), can be beneficial to better understand 
a clinical intervention, efficiently conduct long-term analyses of effects of interventions 
beyond the duration of the clinical trial, improve clinical operations, etc. The sponsor is 
seeking to link clinical trial data and RWD to attain these goals. However, subject IDs are 
unique and internal to each trial and do not provide a way to link subjects across RWD 
datasets. To better understand the long-term effects of interventions, a unique, 
de-identified ID that is common across data sources and is consistent with Health 
Insurance Portability and Accountability Act (HIPAA) standards is required. This is 
achieved through a process called tokenization.
10.4.1 Process and Methodology
Tokenization is the process of removal of identifiers from Personal Identifiable 
Information (PII) and replacing them with a unique token. A token is a universal, 
de-identified key that can be used to link subjects across datasets. Tokens are created 
based on elements of PII. Tokens are secure and can be consistently used without 
unblinding the trial or compromising the privacy of the trial subjects.
Tokens are irreversible and blinded, so subjects cannot be identified from such data. 
Tokens are created by [CONTACT_851981] (tokens) 
from which PII cannot be recovered. The tokens cannot be back engineered to identify 
the PII used to create the tokens, hence they protect subject privacy. Each token created is 
unique to the input PII, thus avoiding false matches. Multiple tokens can be created from 
different PII elements, improving the precision of matching. The same set of input PII 
will always create the same tokens, hence tokens are consistent.
Multiple tokens derived from different PII elements are created for each subject to enable 
accurate matching.
All subjects who have consented to participate in the trial will be given the opportunity to 
provide consent for tokenization. Participation in the tokenization is optional and subjects 
who decline to participate in the tokenization process will still be able to participate in the 
trial outside of the tokenization and linking to external databases. For subjects who 
provide consent to tokenization, no additional trial procedures beyond what is outlined in 
the protocol will be completed as a result of their participation in the tokenization.
The subjectâ€™s tokenized data will be available for linking to other future data for a period 
of [ADDRESS_1184646] Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
88
Protocol No. 345-201-[ZIP_CODE]
89
Confidential - Proprietary Information Approval: [ADDRESS_1184647]â€™s token that has already been created, since the parent PII 
information used to identify the trial subject will be destroyed and the sponsor will not be 
able to reidentify the trial subject. The sponsor cannot remove the subject data that is 
already part of larger datasets that have been and are being shared with other parties for 
further research.
Withdrawal of consent for participation in the trial does not mean withdrawal of consent 
for tokenization. To withdraw tokenization consent, the subject must contact [CONTACT_471301].Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
89
Protocol No. 345-201-[ZIP_CODE]
90
Confidential - Proprietary Information Approval: 03 Nov 202110.5 Appendix 5: Abbreviations
Abbreviation Definition
AE Adverse event
ADT Antidepressant therapyATRQ Antidepressant Treatment Response QuestionnaireCBT Cognitive behavioral therapyCFR Code of Federal RegulationsCGI-S Clinical Global Impressions-SeverityCIOMS Council for International Organizations of Medical ScienceCRO Clinical research organization
C-SSRS Columbia-Suicide Severity Rating Scale
DMC Data Monitoring Committee
DSM-[ADDRESS_1184648] observation carried forwardM.I.N.I Mini International Neuropsychiatric InterviewMADRS Montgomery-Asberg Depression Rating Scale
MAR Missing at random
MDD Major depressive disorder
MDE Major depressive epi[INVESTIGATOR_851927]-ATRQ [LOCATION_005] General Hospi[INVESTIGATOR_307] - Antidepressant Treatment 
Response Questionnaire
MMRM Mixed model repeated measurementsMNAR Missing not at random&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCICCICCI
CCI
Protocol No. 345-201-[ZIP_CODE]
91
Confidential - Proprietary Information Approval: [ADDRESS_1184649]
US [LOCATION_002]
W Week
WHODAS World Health Organization Disability Assessment ScheduleClinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
91
Protocol No. 345-201-[ZIP_CODE]
92
Confidential - Proprietary Information Approval: 03 Nov 202110.6 Appendix 6: Protocol Amendments
The investigator will not make any changes to this protocol without the sponsorâ€™s prior 
written consent and subsequent approval/favorable opi[INVESTIGATOR_1686]. Any permanent 
change to the protocol, whether an overall change or a change for specific trial site(s), 
must be handled as a protocol amendment. Any amendment will be written by [CONTACT_103]. Each amendment will be submitted to the IRB, as required by [CONTACT_427]. 
Except for â€œadministrativeâ€ or â€œnonsubstantialâ€ amendments, investigators will wait for 
IRB approval/favorable opi[INVESTIGATOR_331643](s). Administrative amendments are defined as having no effect on the safety of 
subjects, conduct or management of the trial, trial design, or the quality or safety of 
CT-[ADDRESS_1184650] to subjects should be implemented immediately after agreement by [CONTACT_331694], followed by [CONTACT_331695]. 
The sponsor will submit protocol amendments to the applicable regulatory agencies 
within local applicable timelines.
When the IRB investigators, and/or the sponsor conclude that the protocol amendment 
substantially alters the trial design and/or increases the potential risk to the subject, the 
currently approved written ICF will require similar modification. In such cases, after 
approval/favorable opi[INVESTIGATOR_331644], repeat written informed consent 
will be obtained from subjects enrolled in the trial before expecting continued 
participation and before the amendment-specified changes in the trial are implemented.Clinical Study Report 345-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
92
Protocol No. 345-201-[ZIP_CODE]
93
Confidential - Proprietary Information Approval: 03 Nov 2021&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
94
Confidential - Proprietary Information Approval: 03 Nov 2021&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
95
Confidential - Proprietary Information Approval: 03 Nov 2021&OLQLFDO6WXG\5HSRUW 3URWRFRODQG3URWRFRO $PHQGPHQWV
8QWLOWKHLQIRUPDWLRQKHUHLQLVUHOHDVHGE\2WVXNDWRWKHSXEOL FGRPDLQWKHFRQWHQWVRIWKLVGRFXPHQWDUH2WVXND
FRQILGHQWLDOLQIRUPDWLRQDQGVKRXOGQRWEHGXSOLFDWHGRUUHGLV WULEXWHGZLWKRXWSULRUZULWWHQFRQVHQWRI2WVXND
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
T hi s p a g e i s a m a nif e st ati o n of a n el e ctr o ni c all y c a pt ur e d si g n at ur e 
SI G N A T U R E P A G E 
D o c u m e nt N a m e: Pr ot o c ol A m e n d m e nt 2 3 4 5- 2 0 1- 0 0 0 0 2 
D o c u m e nt N u m b er: 
D o c u m e nt V er si o n: 6. 0 
Si g n e d b y M e a ni n g of Si g n at ur e S er v er D at e 
( d d- M M M- 
y y y y h h: mi n) - 
U T C ti m e z o n e 
Bi o st ati sti c s A p pr o v al 0 3- N o v- 2 0 2 1 
2 0: 0 8: 1 0 
Cli ni c al A p pr o v al 0 4- N o v- 2 0 2 1 
1 3: 5 4: 5 6 
Cli ni c al A p pr o v al 0 9- N o v- 2 0 2 1 
1 7: 3 0: [ADDRESS_1184651] u d y Re p ort 3 4 5- 2 0 1- 0 0 0 0 2 1 6. 1. 1 Pr ot oc ol a n d Pr ot oc ol A me n d me nts 
U ntil t he i nf or m ati o n herei n is rele ase d b y Ots u k a t o t he p u blic d o m ai n, t he c o nte nts of t his d oc u me nt are Ots u k a 
c o nfi de nti al i nf or m ati o n a n d s h o ul d n ot be d u plic ate d or re- distri b ute d wit h o ut pri or writte n c o nse nt of Ots u k a. 
1 0 3 C CI 
P P D 